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ABSTRACT 
Katsuhiko Sueda: Orally Administered Penta-Ethyl Ester Prodrug of DTPA for the Decorporation 
of Americium-241 
(Under the direction of Michael Jay) 
 
Diethylenetriaminepentaacetic acid (DTPA) is an intravenously administered chelating 
agent that is used to facilitate the elimination of 241Am from contaminated individuals. Despite its 
long history of use in chelation therapy, its optimal dose has not been clearly established. To 
evaluate the potential of DTPA to bind 241Am under biological conditions, in vitro binding studies 
were conducted in rat, beagle, and human plasma. Dose-response curves for DTPA were 
established, and DTPA was determined to be most efficient in human plasma and least efficient 
in rat plasma. These results suggest that species differences must be considered when 
translating the efficacy of DTPA from animals to humans. 
The oral delivery of DTPA is challenged by its permeability-limited bioavailability, limiting 
its utility in mass casualty emergencies. To overcome this limitation, a prodrug strategy using 
the penta-ethyl ester of DTPA was explored. Initial assessments of the prodrug identified 
favorable physicochemical properties for oral delivery. Consistent with the measured pKa 
values, the prodrug exhibited pH-dependent solubility and lipophilicity of a weak base that is 
suitable for absorption. Caco-2 permeability assay confirmed the improved epithelial transport of 
the prodrug over DTPA. From in vitro assessments, the prodrug appeared to be sufficiently 
stable against premature hydrolysis during gastrointestinal transit. 
The prodrug was further evaluated in pharmacokinetic, biodistribution, and efficacy 
studies in rats.  A single dose oral administration of the prodrug demonstrated significant 
absorption over 24 h based on the urinary excretion data. From the urine composition, 
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bioactivation was determined to be extensive but incomplete. Tissue distribution at 12 h was 
limited primarily to the gastrointestinal tract. A single dose intravenous administration of the 
prodrug resulted in significant fecal excretion, indicating that biliary clearance is also important 
to the elimination process. From the pharmacokinetic analysis, the oral administration of the 
prodrug appeared to be exhibit favorable characteristics for decorporation, including some 
potential improvements over intravenously administered DTPA. In rats contaminated with 241Am 
by inhalation, a single dose treatment with the prodrug significantly enhanced decorporation 
compared to placebo. Overall, DTPA penta-ethyl ester exhibited promising physicochemical, 
pharmacokinetic, and therapeutic attributes as an orally administered prodrug of DTPA for 
radionuclide decorporation. 
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CHAPTER 1: INTRODUCTION 
 
The growing threat of nuclear terrorism in the United States has become a priority 
concern for national security in recent years; yet, few medical treatments against these threats 
are available. Currently, only six medications to treat radiation exposure are available in the 
Strategic National Stockpile (SNS), a national repository that provides access to medicines in 
the event of a medical crisis. Moreover, these medications are not suited to treat the broad 
range of exposures and injuries that may result from the widespread release of radioactive 
materials or attacks with radiological weapons. To increase the availability of medical 
countermeasures against such threats, a research program has been established by National 
Institute of Allergy and Infectious Disease to accelerate and promote the development of new 
products (1;2). With the support of this program, this project is intended to develop an improved 
therapeutic agent that can facilitate the removal of internalized radioactive contaminants from 
the body. 
Chelation therapy for the removal of internalized radionculides has a long history. The 
therapeutic strategy relies on the use of chelating agents that can effectively sequester metal 
ions inside the body and facilitate their excretion. The underlying mechanism for decorporation 
is to accelerate the elimination of radionuclides from the body to reduce the amount that is 
available for retention (3;4). By reducing the accumulation of the radionuclides, the radioactive 
doses and the risks associated with their radiological effects can be reduced. Numerous 
variants of chelating agents have been synthesized and evaluated over the years. Yet, a 
versatile and easy-to-use chelating agent that is capable of binding to a wide range of metals 
and extracting them from various parts of the body remains to be seen.  
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Diethylenetriaminepentaacetic acid, or DTPA, is the most widely used chelating agent 
for metal detoxification. It is a polyaminocarboxylate ligand that possesses five carboxylic acids 
and three tertiary amines for a total of eight potential coordination sites, which gives it the ability 
to bind a broad range of metals with high affinity. The binding constants for some biologically-
relevant metal ions are listed in Table 1 (5-8). In addition to its use as a therapeutic, DTPA is 
used in medical applications for diagnostic purposes as a carrier for metals that serve as 
contrast agents for magnetic resonance imaging (9). Beyond its medical use, DTPA is used to 
isolate metal ions for various other industrial applications, including uses in food, cosmetics, 
agriculture, textile, and paper/pulp manufacturing (10;11).  
For chelation therapy, DTPA is FDA-approved as Ca-DTPA and Zn-DTPA to treat 
contaminations involving plutonium, americium, and curium. Ca-DTPA and Zn-DTPA are 
administered intravenously at a 1 g daily dose of the tri-sodium salts (12;13). Upon injection, 
DTPA distributes readily in blood, where the calcium and zinc ions are exchanged for 
transuranic elements with higher binding affinity. DTPA itself is excreted rapidly in the urine by 
glomerular filtration (14-16), and the renal excretion of metals can be enhanced by binding them 
with DTPA. The blood serves as the primary site of action for capturing the radionuclides, and 
DTPA undergoes minimal protein binding and metabolic change in the body (14-16). The high 
affinity of DTPA for metal binding also contributes to its toxicity, mostly associated with the 
depletion of essential metals such as zinc, manganese, and magnesium (17). 
Americium is one of three actinides that are approved for treatment with DTPA. All of its 
isotopes are radioactive and in terms of health risks, 241Am is isototpe of most concern as it 
decays with the release of high energy radiation and a long half-life of approximately 432 years. 
The radioactive decay of 241Am involves the conversion to neptunium-237 and the emission of 
an α-particle possessing 5.486 and 5.443 MeV of energy (18;19). The α-particles from the 
decay of 241Am travel only short distances but are energetic, sufficient to cause adverse health 
effects (18). Exposure alone is not likely to cause immediate death, but internalized 241Am can 
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accumulate in the body for long periods (18-20). Over time, cells at the accumulation site may 
be exposed to significant doses of radiation, causing damage to the genetic contents and 
increasing the likelihood of producing cancer (18). The decay process also emits low energy γ-
rays of 0.059 MeV (19), which is utilized in this work to assay for 241Am using a gamma 
scintillation detector. 
Americium is a synthetic element, and 241Am is produced by neutron irradiation of 239Pu 
to form 241Pu, which decays to 241Am (19). In its purified form, it is used at low levels in ionization 
smoke detectors and has applications for thickness and radiographic measurements (19). It is 
found most abundantly in spent nuclear fuel as a byproduct of uranium and plutonium 
processing. Widespread exposure to this radioisotope can occur as a result of release from 
nuclear reactor facilities or detonation of nuclear devices. Terrorists can potentially gain access 
to this radionuclide by raiding nuclear waste facilities, and in combination with conventional 
explosives, spread the radionuclide in the form of radiological dispersal devices, or ‘dirty 
bombs.’ Whether the release is deliberate or accidental, 241Am can spread in the form of 
particles or dust and enter the body by breathing, eating, or drinking contaminated materials. 
The most probable routes of contamination with 241Am are ingestion, inhalation, or 
uptake through wounds. Once absorbed into the blood, greater than 90% of the 241Am resides in 
the plasma fraction, where it binds to plasma proteins, such as transferrin, albumin, α- and β-
globulins, and other endogenous small molecular weight ligands (6;21-23). Some key 
endogenous ligands and their corresponding stability constants for 241Am are listed in Table 2 
(6;7;20). Soon thereafter, 241Am is translocated to the skeleton and liver from where it is 
excreted slowly with elimination half lives of 50 and 2.5 years, respectively (18;20). Due to the 
tendency for 241Am to accumulate in these tissues, these organs are particularly at risk of 
radiological toxicity. 
DTPA is a proven treatment to remove internalized 241Am, primarily by intercepting the 
radionuclide during translocation to the deposition sites. The blood is the primary site of action 
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for DTPA, though alternative sites for decorporation likely exist (24). DTPA binds to 241Am with 
high affinity, possessing a stability constant of 1026.2 M-1. In blood, the high affinity for 241Am 
enables DTPA to compete with endogenous ligands and direct the elimination of the 
contaminant. Empirical evaluations have been used to propose that a DTPA:actinide molar ratio 
of 106:1 may be required for effective decorporation (25). However, the effectiveness of DTPA 
diminishes with time after contamination as 241Am deposits into tissues (26). The hydrophilic 
nature of DTPA limits its ability to gain access to the tissue compartments and facilitate the 
removal of radionuclides from these deposition sites. For treatments such as DTPA that have 
limited ability to facilitate decorporation from intracellular compartments, immediate treatment is 
needed to intercept the radionuclide before tissue deposition. 
The efficacy of DTPA has been studied extensively in animal models, most commonly in 
rats and beagles (16;27). A standard efficacious dose for intravenous administration has been 
established as 30 µmol kg-1 (16). A single, IV bolus injection of DTPA at the standard dose in 
rats administered 1 h after IV contamination with 241Am citrate resulted in the cumulative 14 day 
urinary decorporation of approximately 43% of the injected 241Am, compared to 11% in the 
control group (24). Meanwhile, delivery of DTPA by inhalation also has been shown to provide 
significant therapeutic benefits. However, the rationale for the standard dose, regardless of the 
delivery route, is not clearly evident based on a review of published reports, and the selection 
appears to be mostly driven by empirical assessments (25). 
The efficacy of DTPA in humans have also been reported but, to a much lesser extent. 
The most notable demonstration of efficacy came from the aftermath of the 1976 Hanford 
americium accident, where a worker at the nuclear production facility in Hanford, WA was 
contaminated with 241Am when an explosion occurred. The worker absorbed 241Am in excess of 
1 mCi through the face and neck region, including through burns and lacerations (28). An 
intensive treatment program ensued, using both Ca- and Zn-DTPA injections over a span of 11 
years. In total, greater than 1 mCi of 241Am was excreted over the treatment duration, and based 
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on estimates of the absorbed 241Am dose, the chelation therapy was thought to have prevented 
99% of the internalized 241Am from depositing in the organs (28;29). The therapy during the first 
month included 1 g doses administered every 8 h and thereafter, once daily injections continued 
for years (29). Remarkably, no toxicity was observed (29).  Nonetheless, as this was not a 
controlled clinical study, opportunities to improve the therapy may exist. 
In addition to understanding the in vivo behavior of DTPA, various factors associated 
with the contamination must also be considered when designing an appropriate therapeutic 
regimen. The route of contamination is an important consideration as it can affect the rate of 
entry into the systemic circulation and lead to differences in the availability of the contaminant in 
the blood for chelation by DTPA. Additionally, factors such as solubility, charge, particle size, 
and chemical form of the contaminant can also affect the absorption rate from the point of entry 
(18;30;31). For example, moderately soluble 241Am nitrate can be absorbed relatively quickly, 
while poorly soluble 241Am dioxide may be retained for long periods in the lungs or wounds (17). 
Since the blood is the primary site for chelation, the attributes of the radionuclide and its 
biokinetics in the blood must be considered in order to maximize the therapeutic benefits. 
While the efficacy of DTPA has been demonstrated over the years, as a product of the 
SNS, its method of administration significantly limits its utility in medical emergencies (2). Such 
treatments require a trained medical professional for administration making it difficult to provide 
prompt or repetitive treatments in mass casualty situations. A product that can be administered 
orally and distributed in bulk supply for self-administration would alleviate these issues. 
However, DTPA exhibits poor oral bioavailability, making it unsuitable as a product for oral 
administration. Ironically, the attributes that make DTPA an effective chelating agent also limit 
its utility. The eight coordination sites of DTPA are ionizable functional groups and serve as 
hydrogen bonding sites, resulting in a hydrophilic molecule with high charge density. These 
properties limit the ability of DTPA to effectively penetrate the lipophilic membranes of the 
enterocytes and result in permeability-limited oral absorption (32). 
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To overcome this limitation, a prodrug strategy is proposed. Prodrugs can be created by 
incorporating hydrophobic moieties to the parent compound, yielding a more lipophilic molecule 
(33). The increased lipophilicity could allow for improved permeation through the intestinal 
epithelium and increased uptake into the systemic circulation. The use of a prodrug strategy to 
overcome permeability-limited absorption is an established practice, and prodrugs represent 
approximately 5-7% of the pharmaceutical drugs on the market today (34). Barring significant 
efflux or first-pass clearance effects, a prodrug may be delivered more efficiently than with the 
permeability-limited parent drug. Once absorbed, prodrugs generally rely on metabolism to 
transform into the active parent form and ultimately elicit a therapeutic effect. 
Alternative approaches to increase the bioavailability of DTPA, such as the use of 
nanoparticles or permeation enhancers, have been proposed by other groups (35;36). Size 
reduction, particularly to the sub-micron range, may enable uptake by transcytosis mechanisms 
for transcellular transport. Permeation enhancers may disrupt membranes or efflux effects to 
increase transcellular transport or open tight junctions of the epithelium to increase paracellular 
transport. However, toxicity becomes a concern with these approaches as they can also 
increase uptake of undesired molecules. In the end, these strategies fail to address the poor 
intrinsic property of DTPA that limits its oral absorption and thus, only marginal increases in 
bioavailability were expected. 
In this project, the penta-ethyl ester form of DTPA is proposed as the investigational 
prodrug molecule for oral delivery. The use of carboxylic acid esters is the most common 
prodrug approach (34;37;38), and in the case of DTPA, the five carboxylic acid groups are 
suitable sites for esterification. By masking these ionizable groups with hydrophobic moieties, 
the overall lipophilicity of the molecule can be significantly increased and the potential for 
membrane penetration and absorption may be improved. Although the general use of prodrugs 
to overcome membrane permeability-limited absorption is well established, the use of a prodrug 
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strategy to enhance the oral bioavailability of DTPA has not been reported. Furthermore, ester 
prodrugs beyond the complexity of double esters have not been commercialized (38). 
A prodrug must undergo biotransformation to convert to the therapeutically active form. 
In the case of a carboxylic acid ester prodrug, the activation is a hydrolysis reaction that 
produces an alcohol and a carboxylate and relies on chemical and/or enzymatic catalysis. 
Esterases are a family of enzymes that promote the in vivo hydrolysis of ester-containing 
molecules, including carboxylic acid ester prodrugs (39). They are found extensively throughout 
the body, including the compartments along the oral absorption pathway. The highest enzyme 
activity is generally found in the liver, the primary site of xenobiotic metabolism (39). Among the 
esterases, carboxylesterases are most widely recognized for catalyzing the hydrolysis of 
carboxylic acid esters (39-41). They are particularly efficient at catalyzing the hydrolysis of 
carboxylic esters but can also contribute to the metabolism of many structurally diverse 
molecules (39-41). In the case of DTPA penta-ethyl ester, carboxylesterases may be the most 
important catalyst in its biotransformation to DTPA. 
The penta-ester form of DTPA was chosen for this work primarily to maximize the 
lipophilicty. In addition to the five carboxylic acid groups, DTPA possesses three tertiary amines, 
which are also ionizable. Lipophilicity estimation using ClogP, as shown in Table 3 (42), 
revealed significant increases in ClogP with each ester addition. As a general rule of thumb, a 
molecule with a logP value of 2-3 is considered to possess a good balance between solubility 
and lipophilicity for oral delivery (43). Based on this assessment, the lower degrees of 
esterification on DTPA may be inadequate to sufficiently increase the lipophilicity for enhanced 
oral absorption. Although the tetra-ethyl ester may seem fitting, it was not selected due to the 
complexity of synthesizing this molecule. This molecule exists in two isomeric forms, and 
controlling the synthesis in a manner that produces only one isomer was considered to be a 
difficult challenge. 
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The lipophilicity assessments with ClogP were also confirmed based on previously 
reported in vivo studies with the mono-, di-, and penta-ethyl esters of DTPA. These studies 
involved the intraperitoneal injection of these esters for the intracellular delivery of DTPA to 
hepatocytes for plutonium decorporation (44;45). These investigations found that the DTPA 
penta-ethyl ester enhanced plutonium decorporation from the liver, but the mono- and di-ester 
forms had no enhanced effects compared to DTPA treatment. It was hypothesized that the 
partially esterified forms of DTPA lacked sufficient lipophilicity to penetrate the membranes of 
the hepatocytes to facilitate intracellular decorporation. Based on empirical and in vivo 
assessments, the penta-ester form of DTPA was thought to be most suitable for this application. 
The ability to deliver DTPA penta-ethyl ester by oral administration was investigated in 
this work.  First, the in vitro binding studies were conducted to determine the concentration of 
DTPA that is required in plasma for the effective chelation of 241Am. The approval of DTPA for 
pharmaceutical use is primarily based on efficacy observed in animal models; thus, the optimal 
dose and plasma concentration have not been fully established. Next, the physicochemical 
properties of DTPA penta-ethyl ester were characterized to assess its oral delivery potential. 
This prodrug approach is proposed to increase the lipophilicity of DTPA for enhanced oral 
absorption, and relevant properties that can affect the oral delivery were evaluated. Permeability 
assessments in cell-based assays were also conducted and are summarized in Appendix 1. 
Finally, the pharmacokinetics, biodistribution, and efficacy from the oral administration of DTPA 
penta-ethyl ester were examined in rats in order to demonstrate oral delivery. Additionally, 
supplemental results from the intravenous administration of DTPA penta-ethyl ester are 
summarized in Appendix 2.  
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Tables 
Table 1 Stability constants of DTPA 
Metal ion log K (M-1) 
Mg2+ 9.3 
Ca2+ 10.7 
Mn2+ 15.5 
Zn2+ 18.6 
Co2+ 19.3 
Ni2+ 20.1 
Cu2+ 21.5 
Cr3+ 22.1 
Cm3+ 23.0 
Am3+ 26.2 
Fe3+ 27.8 
Pu4+ 29.5 
 
Table 2 Stability constants of 241Am 
Ligand log K (M-1) 
Acetate 2.0 
Lactate 2.4 
Glycine 4.1 
Cysteine 4.2 
Oxalate 4.8 
Glutamate 5.6 
Carbonate 5.8 
Aspartate 6.1 
Citrate 8.6 
Transferrin 10.4 
 
Table 3 Lipophilicity of DTPA esters 
Molecule ClogP 
DTPA -2.9 
DTPA mono-ethyl ester -2.4 
DTPA di-ethyl ester -1.9 
DTPA tri-ethyl ester 0.3 
DTPA tetra-ethyl ester 2.5 
DTPA penta-ethyl ester 4.7 
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CHAPTER 2: SPECIES-DEPENDENT EFFECTIVE CONCENTRATION OF DTPA FOR 
CHELATION OF 241AM1 
 
Introduction 
The growing threat of nuclear terrorism and the heightened awareness of the potential 
for nuclear accidents have renewed the interest in the development of medical treatments to 
prevent and treat radiation exposure. Among the drugs of interest is 
diethylenetriaminepentaacetic acid (DTPA), a chelating agent used as a first-line treatment for 
individuals that have been contaminated with transuranic radionuclides (46). With a long history 
as an effective decorporation agent, DTPA is made available in the United States Strategic 
National Stockpile for use in medical emergencies as the calcium and zinc chelates of DTPA 
(Ca- and Zn-DTPA). However, the utility of Ca- and Zn- DTPA is constrained by the need for 
intravenous (IV) administration, which requires trained medical personnel for treatment and 
limits their accessibility in mass-casualty situations. To overcome this limitation, alternative 
formulations and delivery strategies with DTPA are being sought (35;36;47;48), with the 
potential to expand the use of DTPA under the United States Food and Drug Administration 
(FDA) Animal Rule. 
The FDA Animal Rule permits the approval of drugs using animal efficacy data when 
human efficacy trials are neither ethical nor feasible. This is an important policy for the 
development of decorporation agents such as Ca- and Zn-DTPA, since human trials are 
restricted to subjects of accidental contamination for ethical reasons. Despite the long history of 
                                               
1
 This chapter previously appeared as an article in Health Physics. The original citation is as follows: 
Sueda K, Sadgrove M, Jay M, DiPasqua AJ. Species-dependent effective concentration of DTPA in 
plasma for chelation of 
241
Am. Health Phys 2013;105(2):208-214. 
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DTPA for use in radionuclide decorporation, its proven efficacy is still mostly limited to studies 
conducted in animal models. Of the animal models, rat and dog (beagle) represent the most 
commonly used species, and an IV bolus dose of 30 µmol kg-1 has been established as the 
standard efficacious dose (16;27). The same weight-normalized dose is also used in humans, 
yet an understanding of the optimal dose and blood levels in humans for therapeutic effect has 
not been clearly established (30). An empirical analysis of existing data has been used to 
suggest that a DTPA:actinide molar ratio of 106:1 in plasma may be required for effective 
decorporation (25). However, as existing human efficacy data are from uncontrolled studies, 
uncertainties in the physicochemical form of the radionuclide, route of exposure, and extent of 
contamination make it difficult to fully characterize the effect of the chelation therapy (49). While 
the use of the animal models has played a pivotal role in demonstrating the potential of DTPA 
for chelation therapy, further work is needed to evaluate the relationship between the animal 
models and humans for optimizing efficacy. 
In an effort to better understand the suitability of animal models for human efficacy 
predictions, in vitro experiments were conducted to characterize the binding of 241Am by DTPA 
in the plasma of rat, beagle, and human. DTPA forms stable chelates with 241Am, possessing a 
high stability constant of 1026.2 M-1 (6). Plasma represents the primary site of action for DTPA 
and contains endogenous ligands that can compete with DTPA for the formation of 241Am 
complexes. In blood, greater than 90% of the 241Am resides in the plasma component (whole 
blood minus blood cells), with approximately 30% bound to the iron-transport protein, 
transferrin, and the remainder to albumin, globulins, and various low molecular weight ligands 
(22;23). Internalized 241Am is transported in blood before depositing in the skeleton and liver, 
from where it is excreted very slowly with elimination half-lives of 50 and 2.5 years, respectively 
(18). Intercepting the 241Am in the blood prior to its deposition in tissues has been proven to be 
an effective treatment approach in both animals and human. A better understanding of the 
chelation potential of DTPA in blood could be useful to improve the dosing regimen and to 
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support the development of alternative DTPA products within the framework of the FDA Animal 
Rule. 
 
Materials and Methods 
The competition between plasma proteins and DTPA for the binding of 241Am in blood 
was characterized by in vitro experimentation. Various concentrations of DTPA were reacted 
with 241Am in rat, beagle, and human plasma before separation and assay. All samples were 
prepared using fixed volumes of the constituents by combining 385 µL of plasma, 8 µL of DTPA 
solution, and 7 µL of 241Am solution. The concentrations of DTPA and 241Am were altered by 
adjusting their stock concentrations. Plasma with sodium heparin (Lampire Biological 
Laboratories, Pipersville, PA) were filtered through a 0.45µm pore size polypropylene 
membrane with a borosilicate glass fiber pre-filter before use. The DTPA stock solutions were 
prepared by dissolving crystalline DTPA (Thermo Fisher Scientific, Morris Plains, NJ) in 10 mM 
sodium phosphate buffer at pH 7.4, and diluting with de-ionized water as needed. Following its 
addition to plasma, the final concentrations of DTPA were 1.67–53.4 µM in rat plasma, 1.67–
26.7 µM in beagle plasma, and 0.84–26.7 µM in human plasma. Commercially available Ca- 
and Zn-DTPA (Heyl Chemisch-Pharmazeutische Fabrik GmbH & Co. KG, Berlin, Germany) 
were used and diluted in a similar manner with de-ionized water before use. The 241Am stock 
solutions were prepared by diluting 241AmCl3 in 1 M hydrochloric acid (Eckert & Ziegler Isotope 
Products, Valencia, CA) with 1% citrate acid solution. The addition of 241Am citrate to the 
mixture of DTPA and plasma in the final addition step yielded a concentration of 3 nM in the 
reaction mixture. In cases where lower 241Am levels were used, the 241Am citrate stock solution 
was diluted with de-ionized water before addition to the reaction mixture.  
Immediately after combining the components, the samples were incubated for 0.5 h on a 
heating block at 37 °C. The solutions were then transferred to Amicon Ultra centrifugal filter 
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devices fitted with an Ultracel 3K membrane (Millipore, Billerica, MA) and centrifuged at 14,000 
×g for 0.5 h to extract protein-bound 241Am. A bicinchoninic (BCA) assay was used to confirm 
that ultrafiltration successfully removed the proteins in the filtrates during preliminary work. 
Filtrates from the filter devices were transferred to Pierce Strong Cation Exchange Spin 
Columns (Thermo Fisher Scientific, Rockford, IL) that had been pre-conditioned with 0.8 M 
ammonium hydroxide and water to separate positively charged 241Am species from negatively 
charged DTPA-bound 241Am. After centrifuging the spin columns at 2,000 ×g for 5 min, the initial 
eluents were collected as the DTPA-bound 241Am fraction. The positively charged 241Am species 
retained on the column were subsequently eluted with two 400 µL aliquots of 1 M nitric acid by 
centrifuging at 2,000 ×g for 5 min each. This separation method was validated by replacing 
plasma with 25 mM 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES) or carbonate 
buffers at pH 7.4 and performing the chromatography in the presence and absence of DTPA. 
The 241Am content in each sample fraction was measured by gamma scintillation counting 
(Perkin Elmer Model 2470 Gamma Counter, Waltham, MA). Background-corrected radioactivity 
was quantified over 30 min using a 40-80 keV energy window to measure the 59.7 keV photon 
emission associated with 241Am decay. 
Dose-response curves were constructed by calculating the fraction of total 241Am that 
was bound to either DTPA or plasma proteins. The sigmoidal regression profiles were 
generated by Gauss-Newton non-linear least squares regression analysis using Statistica 8.0 
(StatSoft, Tulsa, OK). The regression applied the logistic equation (50), 
  
 
         
 
where a describes the slope as the curve approaches the asymptote, b is the inflection point, c 
is the asymptote, and x is the concentration of DTPA that corresponds to y, the fraction of bound 
241Am. The EC90 values were determined by setting y equal to 90% of the c term and calculating 
for x. The 90% level was chosen since it represented a point along the dose-response curve 
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that was approaching the asymptote and did not appear to be distinguishable from the 
asymptote based on the variability of the data. The same regression analysis was applied to the 
data for 241Am-protein binding; however, a transformation was applied to yprotein such that,  
                
where y’ was used for the regression analysis. Subsequent reversal of the transformation 
produced the final binding curves. 
 
Results 
The suitability of the separation method was confirmed during preliminary work as 
follows. The ultrafiltration step was used to isolate the protein-bound 241Am species and cation-
exchange chromatography was used to separate the negatively charged 241Am-DTPA 
complexes from positively charged 241Am species. Specifically, a BCA assay showed that only 
0.6% of the proteins were present in the filtrate after ultrafiltration of the plasma mixture, 
confirming the successful removal of proteins from the plasma. To evaluate the separation of 
the 241Am species by cation-exchange chromatography, similar binding experiments were 
performed in the presence and absence of DTPA while replacing plasma with HEPES and 
bicarbonate buffers. In the absence of DTPA, only 2% of the input 241Am was detected in the 
initial eluent from the chromatographic separation. In contrast, when DTPA was present, 
approximately 85% of the 241Am was measured in the eluent. 241Am in solution exists in the +3 
oxidation state (19), and the effect of DTPA on the elution of 241Am is consistent with the 
expectation that 241Am forms a negatively charged complex with DTPA at physiological pH. 
These preliminary results confirmed that the separation method could adequately separate 
241Am bound by proteins from those chelated with DTPA. 
The dose-response curves for the binding of 241Am by DTPA and proteins in rat, beagle, 
and human plasma are shown in Figure 1. DTPA and plasma proteins exhibit opposing 
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sigmoidal 241Am binding profiles, indicative of a competitive binding relationship. The logistic 
equation parameters for the DTPA regression models are summarized in Table 4. The models 
achieved goodness of fit (R2) of greater than 0.92 in all cases. While some residual loss of 
sample occurred during the separation and transfer steps, greater than 90% of the total input 
241Am was recovered. Of the total 241Am recovered, less than 10% corresponded to the low 
molecular weight, positively charged 241Am species. These were considered to be associated 
with the small organic and inorganic ligands of low 241Am affinity that are present in blood, such 
as chlorides, carbonates, citrates, aspartates, and glutamates (6). The least-squares linear 
regression fits on these data exhibited slopes approaching zero, indicating that they essentially 
remained unchanged with increasing DTPA concentration. 
A comparison of the dose-response curves in rat, beagle, and human plasma reveals 
species differences in the efficiency of DTPA to bind 241Am. A simple comparison of the dose 
response curves in Figure 1 reveals that higher concentrations of DTPA are required in rat and 
beagle plasma than in human plasma to achieve equivalent levels of 241Am chelation. To more 
precisely define the species differences, the EC90 of DTPA in each plasma system were 
determined. From the dose-response curves, it can be noted that approximately 60-70% of the 
total 241Am is maximally bound by DTPA in all species. The EC90 corresponds to the DTPA 
concentration at which the 241Am binding by DTPA is approaching this maximum. In rat plasma, 
the EC90 of DTPA was calculated to be 31.4 µM. In beagle plasma, the EC90 was determined to 
be 15.9 µM, or approximately two-fold lower than in rat plasma. In human plasma, the EC90 was 
even lower at 10.0 µM. While EC90 values reflect DTPA concentrations that maximize 
241Am 
chelation in plasma, these values also correspond to the concentrations at which excess DTPA 
is minimized, thereby reducing the likelihood of binding endogenous metal ions, the primary 
cause of toxicity in DTPA therapies (51). Thus, in a practical sense, the EC90 represents the 
optimal concentration of DTPA in plasma for maximizing chelation while minimizing toxicity. 
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Additional studies were conducted in human plasma to evaluate the effects of variables 
such as 241Am concentration, incubation time, and DTPA complex. When lower concentrations 
of 241Am (0.8 nM) were used, the results did not appear to be significantly different from those 
reported with 3 nM 241Am. This was not unexpected as the concentrations of both DTPA and 
plasma proteins were in great excess relative to 241Am under these conditions. In another study, 
the reaction mixtures were processed after 1.5 and 18 h incubations. Despite the longer 
reaction times, the results did not exhibit differences from data after 0.5 h incubation, suggesting 
that the 241Am-DTPA complexation approaches equilibrium rapidly. 
The input DTPA was also replaced with commercially available Ca- and Zn-DTPA 
preparations in the human plasma system. Both calcium and zinc are endogenous metal ions 
that are present in plasma at concentrations of approximately 10-3 and 10-5 M, respectively, and 
exhibit affinity for DTPA with stability constants of 1010.9 and 1018.6 M-1, respectively (52). 
However, both DTPA complexes exhibit very rapid metal exchange rates in favor of 241Am (52). 
Thus, as expected, the use of these forms of DTPA did not significantly alter the 241Am binding 
behavior based on the comparison of dose-response curves. The lack of differences is likely the 
result of the significantly higher affinity of DTPA for 241Am, 1026.2 M-1, over calcium and zinc ions. 
 
Discussion 
The efficacy of DTPA for radionuclide decorporation in humans has been proven mostly 
through controlled studies in rat and beagle animal models. However, the data presented here 
suggests that different plasma concentrations of DTPA are required in rat, beagle and human to 
effectively chelate 241Am. The results show that DTPA is most effective in human plasma, 
requiring the lowest concentration to maximize the chelation of 241Am. In contrast, DTPA is least 
effective in rat plasma, requiring the highest concentration to effectively bind 241Am. This work 
suggests that species differences in the effectiveness of DTPA must be considered when using 
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rat and beagle animal models to predict the efficacy of DTPA for 241Am decorporation in 
humans. 
The species differences in the effective concentration of DTPA are presumably due to 
differences in their plasma composition; however, the mechanisms underlying these species 
differences remain unknown. Plasma is a complex matrix containing numerous endogenous 
ligands and metals that can interfere with 241Am-DTPA complexation. Transferrin and albumin 
are considered to be the two major endogenous ligands that can compete with DTPA for 241Am 
(22;23), while endogenous metals, such as iron, may compete with 241Am for the binding site of 
DTPA. Since these components are known to differ in plasma concentration depending on 
species (20), additional studies were conducted to explore the effects of these components on 
the dose-response curves. In one study, plasma was replaced with aqueous buffers containing 
isolated transferrin and albumin from rat and human serum at physiologically-relevant 
concentrations to compare the species-specific plasma protein affinity for 241Am in the presence 
of DTPA. As an alternative mechanism, the effect of iron as a competing metal for 241Am was 
investigated by adding ferric citrate or ferric chloride to human plasma at various concentrations. 
However, these studies did not reveal significant shifts in the distribution of 241Am that account 
for the large differences that were observed in the different plasma systems. Taking into 
consideration the complexity of plasma composition and the collective effects that the 
endogenous ligands and metals can have on interaction between DTPA and 241Am, these 
univariate approaches may be inadequate and developing a mechanistic understanding is 
proving to be challenging. 
The effective plasma concentration of DTPA established in this work may be of further 
use to understand the effect of the current dosing regimen in 241Am decorporation. Since 
chelation is dictated by the concentrations of the binding components and plasma represents 
the primary site of action for DTPA, the plasma concentration of DTPA was assumed to be a 
reliable indicator of decorporation efficacy.  With this assumption, the practical significance of 
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the EC90 of DTPA was examined in the context of the previously established pharmacokinetic 
profiles in the different animal models. Following an IV bolus injection of DTPA in humans, the 
plasma concentration profile is expressed as the sum of two exponential components with rate 
constants of 0.28 and 0.0083 min-1 (53). At the current standard dose of 30 µmol kg-1 in a 70 kg 
human subject with a plasma volume of 3 L, the plasma concentration of DTPA is sustained 
above EC90 for approximately 5.6 h after an IV bolus injection. This interpretation is graphically 
depicted in Figure 2a (53). Similar assessments for the animal models estimated the effective 
duration of DTPA to be 40 min in rats and 1.7 h in beagles, also shown in Figure 2b-c (53). 
Beyond these times, the DTPA concentration is too low to overcome the competition with 
endogenous ligands for 241Am binding, and the effectiveness of DTPA is significantly reduced. 
This suggests that the optimal treatment regimen is unique to each species and that increasing 
the dosing frequency from the current once-daily IV bolus injection may be beneficial to sustain 
optimal DTPA blood levels. Consistent with this proposal, the use of multiple injections and 
infusion therapies with DTPA has been demonstrated to improve the therapeutic benefit in 
animal models (54;55). 
A limitation of this type of assessment on the plasma profile of DTPA, however, is that 
the chelation is assumed to occur only in the plasma compartment. While DTPA is primarily 
distributed in the extracellular fluids, studies have indicated that DTPA may also gain entry into 
cells of soft tissues, contributing to delayed or long term decorporation effects (24). Thus, an 
assessment of the plasma compartment alone does not account for the complete mechanism of 
decorporation. A more accurate model for decorporation should also consider the migration of 
DTPA between the extracellular and intracellular compartments. 
In addition to the behavior of DTPA, 241Am and its biokinetics must also be considered 
when determining an optimal DTPA treatment regimen. Since DTPA is most effective in the 
blood compartment, the availability of 241Am during translocation will significantly influence the 
effectiveness of the chelation therapy. It has been shown that DTPA is most effective when the 
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treatment commences as soon as possible after contamination (26). However, both 241Am and 
its DTPA chelate follow complex biokinetics, making it difficult to establish predictive models for 
decorporation (30). The chemical speciation of internalized 241Am and its route of contamination 
are also key variables that affect its rate of absorption into the bloodstream (31). The route of 
contamination can influence the rate at which the radionuclide migrates into the blood; for 
example, contamination via wound or ingestion can result in slower entry into the systemic 
circulation than by inhalation or IV injection. Furthermore, in the case of wound contamination, 
the chemical form dictates the solubility of the 241Am species, thereby affecting the rate of 
uptake into the blood and its retention at the wound site. A slow or prolonged release of 241Am 
from the wound site may necessitate the use of more frequent or extended treatments of DTPA 
to capture the radionuclide during its translocation. While the effective concentration of DTPA in 
blood is only one aspect of the overall decorporation process, the in vitro assessment presented 
in this work provides a basis for exploring further improvements in the current DTPA dosing 
regimen. 
 
Conclusion 
This work provides useful insight into improving the current dosing regimens for DTPA 
and reveals significant species differences in 241Am chelation that may impact decorporation. 
DTPA is most efficient in human plasma, requiring concentrations that are significantly lower 
than in rat or beagle plasma. The results may be further interpreted in the context of plasma 
concentration profiles for DTPA, where the effective duration following a standard treatment  
dose is longest in humans and shortest in rats. These findings offer important considerations in 
translating decorporation efficacy from animal models to humans, a potentially significant 
understanding to support the development of alternative DTPA products under the FDA Animal 
Rule.  
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Tables 
Table 4 Logistic equation parameters and EC90 of DTPA for 
241Am binding 
Plasma 
Parameters for logistic equation (Estimate ± 95% CI) 
R2 EC90 (µM) 
a b c 
Rat 0.18 ± 0.07 19.1 ± 2.9 64.8 ± 8.9 0.922 31.4 
Beagle 0.36 ± 0.07 9.80 ± 0.57 58.3 ± 2.7 0.986 15.9 
Human 0.40 ± 0.13 4.53 ± 0.95 72.0 ± 6.3 0.921 10.0 
Logistic equation:    
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Figures 
 
Figure 1 The competitive binding of 241Am by DTPA and plasma proteins 
The competitive binding of 3 nM 241Am by DTPA (●, solid line) and plasma proteins (○, dotted 
line) after 0.5 h incubation at 37 °C in (a) rat, (b) beagle, and (c) human plasma 
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Figure 2 The effective concentration of DTPA after an IV bolus injection 
The plasma concentration of DTPA after a 30 µmol kg-1 IV bolus injection (solid line) and the 
effective duration (dotted line) in (a) rat, (b) beagle, and (c) human; data adapted from (53)
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CHAPTER 3: PHYSICOCHEMICAL CHARACTERIZATION OF A PRODRUG OF A 
RADIONUCLIDE DECORPORATION AGENT FOR ORAL DELIVERY2 
 
 
Introduction 
Diethylenetriaminepentaacetic acid (DTPA) is a polyaminocarboxylate ligand with eight 
potential coordination sites which makes it effective at binding a broad range of metal ions with 
high affinity.  In medical applications, the tri-sodium salts of calcium- and zinc-DTPA (Ca-DTPA 
and Zn-DTPA) are the agents of choice to treat individuals contaminated with isotopes of the 
transuranic elements americium (Am), curium (Cm), and plutonium (Pu) (12;13).  These α-
particle emitters accumulate rapidly in the skeleton and liver where they are retained with 
biological half-lives of up to 50 years (18;56).  Administration of Ca-DTPA and Zn-DTPA is by 
intravenous (IV) injection whereupon they are rapidly distributed to the extracellular fluids and 
exchange their calcium and zinc ions for the higher-affinity radioactive metals (14;57;58).  
Chelation reduces the tissue distribution of the radionuclides and facilitates their elimination via 
urinary excretion (24).  A single 30 µmol kg-1 IV bolus dose of Ca-DTPA administered 1 h after 
contamination has the potential to remove as much as 45% of internalized 241Am from 
contaminated rats after one day as compared to only 10% in a control group (24).  Similar 
beneficial effects have been demonstrated with Pu and Cm in animal models (16;59;60).  The 
efficacy of DTPA in humans has been demonstrated in victims of accidental contamination, 
most notably from the Hanford Americium Accident (29).  With the growing concern of nuclear 
                                               
2
 This chapter previously appeared as an article in Journal of Pharmaceutical Sciences. The original 
citation is as follows: Sueda K, Sadgrove M, Fitzsimmons JM, Jay M. Physicochemical characterization of 
a prodrug of a radionuclide decorporation agent for oral delivery. J Pharm Sci 2012;101(8):2844-53. 
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terrorism, Ca- and Zn-DTPA are integral components of the United States Strategic National 
Stockpile as countermeasures against radiological threats. 
Despite the effectiveness of the DTPA products, the need for parenteral administration is 
a major limitation for use in a mass causality situation.  Immediate treatment after contamination 
is of upmost importance for effective chelation therapy (26;60).  However, the treatment requires 
a trained medical professional for administration, posing a logistical challenge for treating 
patients quickly and repeatedly.  This is of particular concern in emergency scenarios such as 
the release of radioactivity from nuclear power and waste facilities, or by an act of nuclear 
terrorism including detonation of an improvised nuclear device or a radiological dispersal device 
(‘dirty bomb’).  The costs of manufacturing and maintaining the sterile DTPA products are also 
undesirable.  In contrast, oral dosage forms are generally easier to produce and are convenient 
forms of non-invasive treatments that allow for rapid distribution and self-administration.  
However, DTPA is a highly ionizable, hydrophilic molecule that is poorly absorbed from the 
gastrointestinal tract; in rats, bioavailability has been estimated to be 3% (32).  
In order to improve the oral delivery of DTPA, a prodrug strategy was pursued.  The use 
of prodrugs to overcome permeability-limited absorption is an established practice in drug 
design, and carboxylic acid esters represent one of the most common forms of prodrugs 
(34;37;38).  In the case of DTPA, the five carboxylic acid groups are ideal sites for esterification 
to mask the ionizable groups and render a more lipophilic molecule.  Although lipophilic ester 
prodrugs of DTPA have been studied to improve the intracellular delivery of DTPA after 
parenteral injections (44;45), none have been used for the purpose of oral bioavailability 
enhancement.  It is hypothesized that an appropriately designed ester prodrug of DTPA will 
readily absorb into the bloodstream and be metabolized to the therapeutically active form by 
enzymatic hydrolysis during first-pass metabolism. 
The lipophilicity of a DTPA ester prodrug can be modified by altering the number of ester 
substitutions and/or the length of the alkyl side chain on the esters.  In prior work, parenteral 
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injections of the mono-, di-, and penta-ethyl esters of DTPA were investigated to enhance the 
uptake of DTPA into hepatocytes for the intracellular decorporation of plutonium (44;45).  These 
studies revealed that while the penta-ethyl ester enhanced the intracellular decorporation of 
plutonium, the mono- and di-ester forms had no enhanced effects compared to conventional 
DTPA.  This suggested that partial esterification using short alkyl side chains may be 
inadequate to sufficiently increase lipophilicity for enhanced membrane permeability.  However, 
when more hydrophobic side chains (C12 and C22) were used to form the mono-ester of 
triethylenetetramine, a chelator similar in structure to DTPA, the modification significantly 
improved americium decorporation from the liver following oral administration (61;62).  This 
indicated that the formation of a single ester with a long alkyl chain can sufficiently increase 
lipophilicity to enhance cell membrane penetration. 
In addition to lipophilicity, the molecular weight of the prodrug and toxicity of the alcohol 
moiety liberated from ester metabolism were considered in the prodrug selection.  Larger 
aliphatic alcohols are more hydrophobic but are also generally more toxic (63).  Thus, while 
esters with shorter alkyl side chains can yield smaller prodrug molecules that release alcohols of 
lower toxicity, multiple ester substitutions were considered to be necessary to significantly 
increase lipophilicity over DTPA.  Alternatively, a prodrug with longer alkyl chains on the esters 
may require fewer substitutions for lipophilicity enhancement but, the viability of this type of 
prodrug may be limited by its large size and toxicity.  Following an initial screening of various 
DTPA prodrugs for their radionuclide decorporation efficacy (64), the penta-substituted ethyl 
ester prodrug of DTPA was ultimately chosen for further development.  
The physicochemical properties of DTPA penta-ethyl ester as it relates to oral drug delivery 
potential are presented here.  In addition, as it may be difficult to characterize the bioavailability 
and potentially complex metabolic behavior of this prodrug, a preliminary in vivo efficacy study 
was conducted to infer its oral delivery potential.  The results of these studies will be used to 
26 
 
identify formulation strategies to support progression into in vivo bioavailability and detailed 
efficacy studies. 
 
Experimental Methods 
Synthesis and Identification 
The DTPA penta-ethyl ester was synthesized by an acid-catalyzed esterification 
process, reacting DTPA with ethanol in the presence of hydrochloric acid (64), as shown in 
Figure 3.  The reaction yielded a clear, light yellow, slightly viscous liquid. The identity of the 
liquid product was confirmed to be DTPA penta-ethyl ester by 1H-NMR, elemental analysis, MS, 
and HPLC.  1H-NMR was performed using a Varian 400 MR NMR spectrometer operating at 
400 MHz.  Elemental analysis was performed for C, H, and N elements by combustion and 
pyrolysis analyses at Atlantic Microlab, Inc.  MS was performed on an Agilent 1100 LC/MSD 
Trap system by direct injection of DTPA penta-ethyl ester dissolved in acetonitrile.  Electrospray 
ionization for MS was performed with nitrogen gas at 8 L min-1 and 45 psi nebulizer pressure, 
and the ion trap mass analyzer was operated in positive ion scanning mode.  Purity was 
measured using a Shimadzu Prominence HPLC equipped with Alltech 3300 evaporative light 
scattering detector (ELSD).  A reverse phase gradient separation was performed using an 
Alltima C18 column (250 × 2.1 mm I.D., 5 µm) at 40°C and a flow rate of 0.25 mL min-1.  The 
solvent that comprised the mobile phase were water with 0.1% trifluoroacetic acid (A), 
acetonitrile (B), and isopropanol (C).  The mobile phase mixture (A:B:C) followed a linear 
gradient from 94:4:2 to 10:60:30 over 6 min, followed by an isocratic phase of 10:60:30 for 4.5 
min.  The ELSD was operated at 40°C with 1.9 L min-1 nitrogen gas flow.  Despite the non-
linearity of the detector and differing response factors associated with impurities, purity was 
estimated by peak area measurement due to the lack of reference standards for each of the 
impurities. 
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Viscosity 
DTPA penta-ethyl ester is a slightly viscous liquid at room temperature.  The viscosity 
and fluid behavior were characterized using a TA Instruments AR-G2 rheometer equipped with 
a 60 mm diameter cone and plate assembly at 25°C.  Testing was performed by varying the 
shear rate over a range of 0.1-1,000 s-1.  With each change in shear rate, steady state was 
achieved before the shear stresses and viscosities measurements were recorded. 
 
Ionization Constant 
The dissociation constants for the conjugate acids of the three tertiary amines of DTPA 
penta-ethyl ester were determined by potentiometric titration.  DTPA penta-ethyl ester was first 
dissolved to a concentration of 2.5 mM in a 0.01 N hydrochloric acid solution and 0.1 N sodium 
hydroxide was added as the titrant.  A pH measurement was obtained with each titrant addition 
using a Fisher Scientific Accumet AB15 Plus pH meter with AccupHast (Ag/AgCl reference) 
glass electrode.  The solution at the end of titration was assayed by HPLC-ELSD to confirm that 
DTPA penta-ethyl ester remained intact. 
 
Solubility 
The apparent solubility of DTPA penta-ethyl ester in aqueous and non-aqueous solvents 
was determined by phase solubility analysis.  The aqueous solvents were prepared as citrate 
and phosphate buffers of 200-600 mM (I = 1 M with sodium chloride) over a pH range of 4-8.  
The non-aqueous solvents were common pharmaceutical co-solvents, vegetable oils, and 
surfactants.  DTPA penta-ethyl ester was combined with each solvent in excess and gently 
agitated on a rotisserie-style shaker for up to 24 h at room temperature.  The supernatant was 
collected by centrifugation and assayed for DTPA penta-ethyl ester content by HPLC-ELSD. 
The pH of the final supernatants was also measured in the aqueous samples to confirm 
adequacy of the buffers. 
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Lipophilicity 
The pH-dependent partition coefficients were determined by measuring the partitioning 
of DTPA penta-ethyl ester between 1-octanol and aqueous buffers.  Phosphate (pH 2 and 7), 
citrate (pH 3), formate (pH 4), acetate (pH 5), succinate (pH 6), and tris (pH 8 and 9) buffers 
were prepared at 200 mM concentration (I = 0.6 M with sodium chloride).  An octantol:aqueous 
buffer volumetric ratio of 1:4 was used to prepare the sample mixtures.  Following the addition 
of DTPA penta-ethyl ester, the samples were gently mixed on a rotisserie-style shaker for 
approximately 24 h at room temperature. Thereafter, the two immiscible phases of the samples 
were separated by centrifugation.  Sample aliquots were obtained from each phase and the 
DTPA penta-ethyl ester content in each phase was measured by HPLC-ELSD.  
 
Chemical and Enzymatic Degradation Rate 
The effect of pH on the degradation rate of DTPA penta-ethyl ester was evaluated by 
monitoring the loss of the DTPA penta-ethyl ester prodrug over time.  Phosphate (pH 2 and 7), 
citrate (pH 3), formate (pH 4), acetate (pH 5), succinate (pH 6), and tris (pH 8 and 9) buffers 
were prepared at concentrations of 50, 100, and 200 mM (I = 0.6 M with sodium chloride).  
DTPA penta-ethyl ester was initially prepared as a stock solution in acetonitrile before diluting 
the stock to a 5% concentration with each buffer.  The starting concentration of DTPA penta-
ethyl ester in the reaction mixture was 1.1 mM.  The buffers were pre-heated in a 37°C oven 
before use, and the reaction mixtures were stored in sealed glass vials in the same oven for the 
duration of the experiment.  At various time intervals, the reaction mixtures were assayed by 
HPLC-ELSD for DTPA penta-ethyl ester content.  The reactions were carried out until at least 
25% loss of the prodrug was observed. 
The enzymatic degradation kinetics of DTPA penta-ethyl ester were also measured in 
simulated gastric fluid (SGF) and simulated intestinal fluid (SIF).  The simulated fluids were 
prepared using porcine pepsin and pancreatin following the formula described in United States 
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Pharmacopeia (65).  The prodrug was dissolved in the pre-heated simulated fluids, and the 
reaction mixtures were maintained at 37°C in a water bath for the duration of the study.  As 
before, the samples were periodically tested by HPLC-ELSD for DTPA penta-ethyl ester 
content. 
 
241Am Decorporation 
 To further assess the oral delivery potential of DTPA penta-ethyl ester, a decorporation 
study was conducted in rats contaminated with 241Am.  The animal study was conducted 
according to a protocol approved by the University of North Carolina at Chapel Hill Institutional 
Animal Care and Use Committee.  Americium chloride (Eckert & Ziegler Isotope Products, 
Valencia, CA) was diluted with a solution of 1% citric acid to prepare a contaminating solution of 
2.5 µCi mL-1, or 30 nmol mL-1.  Adult female Sprague-Dawley rats (Charles River Labs, Raleigh, 
NC) were anesthetized with 2-3% isoflurane using a vaporizer before contaminating them with 
0.1 mL of 241Am citrate via surgically implanted jugular vein catheters.  After injection of 241Am, 
the catheters were flushed with 0.2 mL of 0.9% saline solution, followed by 0.1 mL of heparin 
lock flush solution.  One hour after contamination, rats in the treatment groups received single 
dose treatments of either Ca-DTPA intravenously or DTPA penta-ethyl ester orally.   Ca-DTPA 
(Heyl Chemisch-Pharmazeutische Fabrik GmbH & Co. KG, Berlin, Germany) was diluted with 
saline to a concentration of 0.02 mg/mL before administering it via the jugular vein catheter at a 
26.8 µmol kg-1 dose.  DTPA penta-ethyl ester was diluted to a 2% concentration in soybean oil 
and administered by oral gavage at doses of 37.5 and 75 µmol kg-1.  The rats in this group were 
fasted for 6 h prior to contamination and presented with food 1 h after treatment.  Rats in the 
control group were left untreated after contamination.  For the duration of the study, the rats 
were housed in metabolic cages with daily urine and feces collection until euthanasia at Day 7.   
Following euthanasia, the liver was also collected.  As ~35% of the decay of 241Am is associated 
with photon emissions of 59.7 keV, the urine, feces, and liver samples were assayed for 241Am 
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activity using a gamma counter (Perkin Elmer Model 2470 Gamma Counter).  The 
measurements were background-corrected and counted over one minute using a 10-1000 keV 
energy detection window.  The activity associated with the injected dose of 241Am was also 
determined, and the decorporation results were reported as a percentage of the injected dose. 
 
Results 
Identification 
The product of the synthetic reaction was a clear, light yellow, slightly viscosity liquid 
with a density of 1.14 g mL-1.  The chromatographic analysis identified a primary eluting peak 
with 99.4% peak area. Analyses by 1H-NMR, MS, and elemental analysis confirmed the material 
to be the penta-ethyl ester form of DTPA.  1H-NMR (400 MHz, CDCl3): δ 4.14 (m, 10H), 3.57 (s, 
8H), 3.47 (s, 2H), 2.81 (m, 8H), 1.26 (t, 15H).  MS: m/z calculated 534.3; found 534.7. Elemental 
analysis:  calculated C 54.02, H 8.12, N 7.87; found C 53.34, H 8.03, N 7.76.  
 
Viscosity 
The rheological properties of DTPA penta-ethyl ester were determined by measuring the 
shear stress at both increasing and decreasing shear rates.  The relationship between shear 
stress and shear rate from increasing shear rate, as shown in Figure 4, is linear and passes 
through the origin, indicative of a Newtonian fluid.  A viscosity of 175 cP was measured over this 
range, as evident from the slope of the linear regression equation.  The results obtained by 
decreasing the shear rate were superimposable with those obtained by increasing the shear 
rate, confirming that the material is a Newtonian fluid. 
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Ionization Constant 
Analysis of the titration curve identified three pKa values corresponding to the conjugate 
acids of the three tertiary amines.  The titration curve is shown in Figure 5.  The first derivative 
of the titration curve was used to identify two equivalence points, which were subsequently used 
to identify the three pKa values.  The ionization constants were determined to be 2.93, 6.05, and 
10.87.  HPLC assay of the solution at the end of titration confirmed that greater than 80% of the 
starting DTPA penta-ethyl ester remained.  
 
Solubility 
The apparent solubility of DTPA penta-ethyl ester was measured in aqueous buffers of 
pH 4-8 after 2.5, 5, and 24 h at room temperature.  The measured solubility values did not 
change over time, and the pH-dependent solubility profile at 24 h appears in Figure 6.  Below 
pH 6, the solubility was determined to increase log-linearly with decreasing pH, a profile that is 
consistent with a weak base possessing a pKa of 6.05.  The solubility at low pH conditions, 
despite the use of high buffer concentrations, could not be measured as the buffer capacity was 
exceeded due to the high solubility of the prodrug.  The solubility at high pH conditions also 
could not be measured experimentally due to rapid degradation of the compound. 
The apparent solubility of DTPA penta-ethyl ester was also measured in various lipids 
and organic solvents, listed in Table 5, to identify excipients for formulation development.  The 
solubility of the prodrug was limited in solvents possessing highly polar (water) and highly non-
polar (vegetable oils) properties.  In contrast, solvents of more moderate polarity (co-solvents 
and surfactants) were completely miscible with DTPA penta-ethyl ester at all ratios. 
 
Lipophilicity 
The lipophilicity of DTPA penta-ethyl ester was evaluated by measuring its partitioning 
between 1-octanol and aqueous buffers of pH 2-9.  The logD profile in Figure 7 shows that 
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lipophilicity increases with increasing pH, a trend that is expected for an ionzable weak base.  
Over this pH range, the logD values span a wide range from -0.2 to 2.3, suggesting that pH 
significantly influences the lipophilicity of this prodrug molecule.   
 
Chemical and Enzymatic Hydrolysis Kinetics 
Esters are labile bonds that are prone to chemical and enzymatic hydrolysis (38).  The 
pH-dependent chemical stability was evaluated by incubating dilute samples of DTPA penta-
ethyl ester in aqueous buffers of varying pH at 37°C and assaying for prodrug content over time.  
At all conditions, the loss of DTPA penta-ethyl ester followed pseudo-first order kinetics, and the 
observed rate constants (kobs) were calculated by least squares regression analysis.  The 
observed rate constants are summarized in Table 6.  Buffer catalysis was observed at all pH 
conditions; thus, the adjusted rate constant (kadj) was determined by plotting the observed rate 
constants as a function of buffer concentration and extrapolating the linear regression to zero 
buffer concentration.  The pH-degradation rate profile using the adjusted rate constants is 
shown in Figure 8 and shows a V-shaped profile with the prodrug being most stable at 
approximately pH 4.0-4.5.  
The reaction scheme in Figure 9 is a proposed model for the hydrolysis associated with 
the different ionized species of the prodrug.  The reactions involve the acid-catalyzed hydrolysis 
of the triprotic form (kH), acid-catalyzed hydrolysis of the diprotic form (k’H), base-catalyzed 
hydrolysis of the diprotic form (k’OH), and base-catalyzed hydrolysis of the monoprotic form 
(k’’OH).  The non-linear regression model used to fit the pH-rate profile is given by the equation: 
     
    
      
             
              
          
                         
 
The rate constants were calculated to be kH = 0.5 h
-1 M-1, k’H = 1.4 h
-1 M-1, k’OH = 282,680 h
-1  
33 
 
M-1, and k’’OH = 4101 h
-1 M-1 by regression analysis (R2 = 0.999) using the experimentally 
measured pKa values.  The analysis reveals that the hydrolysis of the DTPA penta-ethyl ester is 
facilitated by general acid- and base-catalyzed reactions. 
The degradation of DTPA penta-ethyl ester also followed pseudo-first order kinetics in 
SGF and SIF.  The observed rate constants at 37°C were 0.028 h-1 in SGF (pH 1.18) and 
0.0059 h-1 in SIF (pH 6.48).  The rate constants were similar to those observed in the pH-rate 
profile at the corresponding pH, as shown in Figure 6.   Furthermore, altering the enzyme 
concentrations did not affect the degradation kinetics (data not shown).  These results suggest 
that these digestive enzymes have minimal effects on the hydrolysis kinetics of DTPA penta-
ethyl ester. 
 
241Am Decorporation 
The efficacy of orally administered DTPA penta-ethyl ester was evaluated in rats 
contaminated intravenously with 241Am.  The decorporation of 241Am over seven days is 
summarized in the total daily excretion profile of Figure 10.  The treatment effects, most 
prominently with DTPA, are apparent in the first three days after treatment.  Thereafter, no 
enhanced decorporation effects are observed over the control group.  An examination of the 
cumulative 241Am excretion data after three days, shown in Table 7, confirms that total 
decorporation was significantly improved with both DTPA and DTPA penta-ethyl ester 
treatments compared to no treatment.  A further breakdown of the urinary and fecal excretion 
data reveals that the improved decorporation with the prodrug is predominantly associated with 
enhanced fecal excretion.  Additionally, the reduction in the liver retention of 241Am after seven 
days, also shown in Table 7, is consistent with observed enhancement in fecal excretion of 
241Am. 
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Discussion 
DTPA penta-ethyl ester is an ionizable weak base with measured pKa values of 2.93, 
6.05, and 10.87.  The pKa values suggest that this molecule remains predominantly ionized over 
the physiological pH range, a factor that may contribute to reduced oral absorption potential.  
The ionization scheme is considered to occur in a manner consistent with DTPA: 1) the central 
amine is first to ionize; 2) the second ionization occurs on one of the outer amines, triggering the 
proton on the central nitrogen to move to the opposing outer amine due to electrostatic 
repulsion; and 3) the final ionization occurs on the vacated central amine (66).  The pKa values 
for the amines of DTPA were reported to be 4.65, 8.45, and 10.02 based on NMR analysis (66).  
The first two pKa values of the amines of the prodrug are lower than those reported for DTPA 
due to the lower electron withdrawing ability of the ester groups compared to carboxylic acids 
(67).  Each ester group contributes to lowering the pKa value of the amines with the reduction 
being most apparent in the second ionization, presumably due to the proton shift necessary for 
that ionization step.  
The pH-dependent properties of solubility and lipophilicity were generally consistent with 
the measured ionization constants.  The profiles show that as pH decreases, aqueous solubility 
of DTPA penta-ethyl ester increases and lipophilicity decreases.  Moreover, as pH decreases 
below pH 6, a log-linear solubility increase is observed, confirming the pKa value of 6.05.  
However, similar analyses could not be applied to the two extreme pKa values due to instability 
of DTPA penta-ethyl ester or inability to control pH.  A more careful examination of solubility 
closer to these conditions may be useful to further define the pH-solubility profile.  Nonetheless, 
aqueous solubility was not considered to be a critical aspect in evaluating oral delivery potential 
since the DTPA penta-ethyl ester is a liquid and thus, dissolution is not a limiting factor in the 
absorption process. 
Lipophilicity was considered to be a more relevant property to evaluate the oral delivery 
potential of this prodrug molecule.  Oral absorption by passive diffusion is generally limited to 
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small molecules of moderate lipophilicity in the unionized form (68;69).  Despite the ionization 
potential, the prodrug partitions favorably into the non-polar octanol phase at physiological pH 
conditions.  The lipophilicity profile shows that logD exceeds 2 at pH greater than 6, a pH 
condition that resembles the intestinal lumen.  Considering that absorption of ingested 
molecules occurs predominately in the intestines, the lipophilicity profile suggests that this 
prodrug may be a good candidate for oral absorption.  Compared to DTPA with a ClogP of -2.9 
(42), the prodrug exhibits significantly higher lipophilicity, which is expected to contribute to 
increased intestinal permeability and absorption. 
A study on the degradation rate of the prodrug in aqueous solution determined that the 
stability is highly pH-dependent.  Over the pH range of 2 to 8, the degradation half-lives ranged 
from 3.6 to 297 days.  As unabsorbed drugs are excreted from the gastrointestinal tract 
generally within one day (70), the prodrug appears to be sufficiently stable against pH effects to 
avoid premature degradation.  In vitro stability evaluations in SGF and SIF also revealed that 
degradation was not accelerated by the presence of pepsin and pancreatin, digestive enzymes 
known to possess esterase activity (71;72).  This provides additional supporting data that the 
prodrug is sufficiently stable to avoid extensive degradation in the gut lumen prior to absorption. 
To support the in vitro assessment of the prodrug’s oral delivery potential, a preliminary 
efficacy study was conducted.  The 241Am decorporation study showed that oral treatments of 
DTPA penta-ethyl ester enhanced 241Am elimination compared to the control group, suggesting 
that the prodrug is capable of being delivered orally.  Moreover, the therapeutic effect appears 
to be dose-dependent, with higher doses exhibiting higher decorporation.  Although the orally 
administered prodrug was less effective than the intravenously administered DTPA at 
comparable doses, this was not surprising, considering the barriers for oral absorption and the 
metabolic activation required for the chelation of 241Am.  Nonetheless, the enhanced fecal 
excretion of 241Am and reduced liver burden produced by DTPA penta-ethyl ester provides initial 
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supporting evidence that DTPA penta-ethyl ester may be a viable prodrug for decorporation 
therapy. 
Based on the liquid nature of DTPA penta-ethyl ester, a possible formulation strategy 
may be to develop an oral solution or a liquid-filled capsule dosage form.  The solubility 
screening in various solvents revealed that the prodrug favors solvents that are neither 
extremely polar nor extremely non-polar.  Solvents that are non-polar (e.g., medium chain 
triglyceride) to moderately polar (e.g., polyethylene glycol 400 and propylene glycol) exhibited 
complete miscibility with the prodrug and may be best suited as diluents to support a liquid 
formulation.  However, protic solvents may be incompatible with the prodrug due to their 
potential to participate in hydrolysis or trans-esterification reactions.  In addition, many of the 
excipients that are highly miscible with the prodrug possess amphiphilic properties, which may 
be useful to facilitate emulsification in a lipid-based delivery system.  The addition of emulsifiers 
may help to form colloidal dispersions that can shield the prodrug from premature chemical and 
enzymatic degradation in the gut lumen.  The emulsifiers may also be useful to support a self-
emulsified drug delivery system (SEDDS), which can enhance bioavailability by entrapping the 
lipophilic drug in micellar or mixed micellar structures that facilitate the transfer of drug to the 
enterocytes across the unstirred water layer (73;74). Despite the high lipophilicity of the prodrug, 
approaches to enhance bioavailability may still be necessary to minimize pill burden, 
considering that the injectable Ca- and Zn-DTPA products are administered at a relatively high 1 
g daily dose and the decorporation study showed lower efficacy of the prodrug at comparable 
doses. 
In addition to treatment convenience, an orally administered prodrug of DTPA may have 
the benefit of eliciting a protracted exposure, thereby improving therapeutic effect.  While the IV 
administration of DTPA has the advantages of complete bioavailability and rapid onset, 
elimination occurs very rapidly with a biological half-life of approximately 0.53 h in rats (47).  To 
compensate for this rapid elimination, treatment regimens using more frequent injections or 
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infusion approaches have been proposed (54;55); however, these are still limited by the 
inconvenience of the treatment, particularly in a mass casualty situation.  In contrast, orally 
administered drugs follow an indirect path to the systemic circulation, and the entry of the drug 
into the bloodstream is not instantaneous.  The slower absorption process or the need for 
metabolic activation may be favorable in extending the duration in which the drug enters the 
bloodstream, thereby reducing the impact of the rapid elimination.  The oral delivery approach 
may also allow for opportunities to modulate the absorption rate and duration by implementing 
modified release drug delivery systems. 
Other factors related to the contaminating radionuclide, such as its chemical form and 
the route of contamination, can influence the biokinetics of the radionuclide and are important 
considerations in identifying the optimal therapeutic regimen (31).  Less soluble forms of the 
radionuclide or contamination via inhalation or through wounds can result in slower entry of the 
radionuclide into the systemic circulation (54).  Therefore, IV administration of DTPA, with its 
subsequent rapid elimination kinetics, may not be the ideal treatment to counteract the slow 
influx of the radionuclide into the blood.  Studies in animal models have shown that radionuclide 
decorporation under these scenarios may be enhanced when repetitive injections or infusion 
therapies of DTPA are implemented (54;55).  As nuclear terror attacks pose threats of 
contamination primarily via inhalation or wounds, an orally bioavailable decorporation agent with 
prolonged effects may be advantageous for overall efficacy and convenience. 
Even with sufficient absorption, the prodrug ultimately needs to undergo metabolic 
activation to liberate the therapeutically active DTPA molecule.  Carboxyesterases are expected 
to be the primary enzymes contributing to the bioactivation of this multi-ester prodrug.  
Esterases are present in various compartments along the absorption pathway, including the 
intestinal epithelium, plasma, and hepatocytes (39;40;75).  Incomplete metabolism could lead to 
reduced efficacy, although the partially hydrolyzed DTPA esters may form chelates with 
transuranic elements, albeit with lower affinity constants, that can impart some therapeutic 
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effect.  Since esterases are prevalent in the liver, significant metabolism in the liver is expected.  
On one hand, metabolism in the hepatocytes could sequester DTPA in the intracellular 
compartment, reducing the amount available in the blood.  On the other hand, as Pu, Am, and 
Cm tend to accumulate in the liver, this prodrug could be beneficial to facilitate decorporation 
from the intracellular compartment of hepatocytes.  Although DTPA has been linked to some 
intracellular decorporation (24), its effects are considered to have a relatively small contribution 
to overall decorporation, limited by its inability to cross cell membranes.  Thus, a lipophilic 
prodrug of DTPA with intracellular activity may serve to complement the effects of the current 
DTPA treatment for enhanced radionuclide decorporation.  Defining the sites and extent of 
metabolism will be crucial to assess the oral delivery and advance this prodrug for further 
development. 
 
Conclusion 
The physicochemical properties of DTPA penta-ethyl ester suggest that it is a promising 
molecule for oral delivery.  Consistent with the measured pKa values, the prodrug exhibits pH-
dependent solubility and lipophilicity properties that are representative of a weak base and 
favorable for oral absorption.  Despite the ionization potential over the physiologically relevant 
pH conditions, the logD measurements indicate that the prodrug may be well-suited for 
membrane permeability in the intestines, the primary site of absorption for most ingested 
molecules.  In vitro stability studies suggest that the prodrug is sufficiently stable against 
chemical and enzymatic degradation in the gut lumen to avoid premature degradation.  An initial 
decorporation study provided indications of dose-dependent efficacy, which suggests that this 
may be a viable orally administered prodrug for chelation therapy.  An oral solution or liquid-
filled capsule dosage form using lipid excipients may be viable options for formulation  
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development.  In vivo investigations of the bioavailability and metabolism are essential steps to 
continue the evaluation of this prodrug as an orally administered radionuclide decorporation 
agent. 
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Tables 
Table 5 Solubility of DTPA penta-ethyl ester at room temperature 
Excipient Apparent Solubility (mg mL-1) 
Water (resulting pH: 7.04) 3 
Peanut oil 98 
Sesame oil 129 
Corn oil 155 
Soybean oil 166 
Ethanol Completely miscible 
Propylene glycol Completely miscible 
Polyethylene glycol 400 Completely miscible 
Caprylic/capric triglyceride (Crodamol GTCC) Completely miscible 
Polyethoxylated castor oil (Cremophor ELP) Completely miscible 
Caprylocaproyl macrogol glyceride (Labrasol) Completely miscible 
Oleoyl macrogol glyceride (Labrafil M1944CS) Completely miscible 
Glyceryl capylate/caprate (Capmul MCM) Completely miscible 
Span 80 Completely miscible 
Tween 80 Completely miscible 
Tween 20 Completely miscible 
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Table 6 Observed rate constants for the hydrolysis of DTPA penta-ethyl ester 
Observed rate constants for the loss of DTPA penta-ethyl ester in aqueous buffers at 37°C; data 
expressed as mean ± 95% confidence interval 
pH Buffer Buffer concentration (mM) kobs (h-1) 
0.30 Hydrochloric acid 600 0.0924 ± 0.0078 
  50 0.00336 ± 0.00047 
2.29 Phosphate 100 0.00421 ± 0.00055 
  200 0.00441 ± 0.00044 
  50 0.000980 ± 0.000081 
3.04 Citrate 100 0.00107 ± 0.00011 
  200 0.00119 ± 0.00010 
  50 0.000206 ± 0.000045 
4.29 Formate 100 0.000239 ± 0.000059 
  200 0.000469 ± 0.000068 
  50 0.000505 ± 0.000063 
5.11 Acetate 100 0.000717 ± 0.000057 
  200 0.00117 ± 0.00008 
  50 0.00190 ± 0.00015 
6.10 Succinate 100 0.00225 ± 0.00012 
  200 0.00313 ± 0.00013 
  50 0.00380 ± 0.00056 
6.81 Phosphate 100 0.00438 ± 0.00034 
  200 0.00649 ± 0.00033 
  50 0.00870 ± 0.00124 
7.92 Tris 100 0.0111 ± 0.0008 
  200 0.0148 ± 0.0014 
  50 0.0371 ± 0.0064 
8.88 Tris 100 0.0398 ± 0.0074 
  200 0.0457 ± 0.0056 
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Table 7 Excretion and liver retention of 241Am after a single dose treatment 
Excretion and liver retention of 0.3 nmol 241Am administered by IV injection after three and 
seven days, respectively, following a single dose treatment in rats; data expressed as mean ± 
95% confidence interval 
Treatment Route N 
Cumulative excretion (% of injected) Liver retention 
(% of injected) In urine In feces Total 
No treatment - 6 7.04 ± 1.98 2.04 ± 0.48 9.08 ± 2.34 22.7 ± 2.9 
DTPA 
26.8 µmol kg-1 
IV 6 16.5 ± 2.2 14.5 ± 2.5 30.9 ± 4.1 7.68 ± 4.73 
DTPA prodrug 
37.5 µmol kg-1 
PO 5 6.86 ± 1.85 7.00 ± 1.46 13.9 ± 2.5 14.2 ± 2.0 
DTPA prodrug 
75 µmol kg-1 
PO 5 10.39 ± 3.87 7.81 ± 3.08 18.2 ± 4.1 13.1 ± 1.9 
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Figures 
 
Figure 3 Synthesis of DTPA penta-ethyl ester 
 
 
 
Figure 4 Rheological profile of DTPA penta-ethyl ester at increasing shear rate 
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Figure 5 Titration of DTPA penta-ethyl ester with sodium hydroxide 
 
 
 
Figure 6 pH-dependent aqueous solubility of DTPA penta-ethyl ester 
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Figure 7 logD of DTPA penta-ethyl ester 
 
 
 
Figure 8 pH-rate profile of DTPA penta-ethyl ester hydrolysis at 37°C 
Experimental values (●) and non-linear regression fit (dotted line) 
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Figure 9 General acid- and base-catalyzed hydrolysis of DTPA penta-ethyl ester 
Reactions include acid-catalyzed hydrolysis of the triprotic form (kH), acid-catalyzed hydrolysis 
of the diprotic form (k’H), base-catalyzed hydrolysis of the diprotic form (k’OH), and base-
catalyzed hydrolysis of the monoprotic form (k’’OH) 
 
 
 
Figure 10 Total daily excretion of 241Am after a single dose treatment 
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CHAPTER 4: ORALLY ADMINISTERED DTPA PENTA-ETHYL ESTER FOR THE 
DECORPORATION OF 241AM3 
 
Introduction 
Americium-241 is a transuranic radionuclide that is found most abundantly in spent 
nuclear fuel as a byproduct of plutonium processing for the production of nuclear power and 
nuclear weapons. Widespread exposure to 241Am can occur by its accidental release from 
nuclear facilities or by the detonation of nuclear devices. It can also be spread on a smaller 
scale by the illicit detonation of radiological dispersal devices, or “dirty bombs.” Contamination 
can occur by inhalation, ingestion, or entry through wounds, and internalized 241Am is 
transported in blood before depositing primarily in the skeleton and liver (6;7;23;76). Once 
deposition occurs, it is difficult to remove the contaminant from the body as current treatments 
have limited efficacy. The potential for chronic exposure to localized radiation following tissue 
deposition makes for a hazardous radionuclide that can cause cancer and other radiation-
induced injuries. 
Intercepting the 241Am in the blood prior to deposition has been proven to be an effective 
treatment approach. The current first-line treatment is diethylenetriaminepentaacetic acid 
(DTPA), a chelating agent that is used to facilitate the excretion of internalized radionuclides, 
including 241Am (46). The treatment usually involves the intravenous administration of the 
trisodium calcium and zinc salts of DTPA, after which these chelating agents distribute to the 
extracellular fluids and are rapidly excreted in urine by glomerular filtration (2;14). DTPA exhibits 
                                               
3
 This chapter will appear as an article in Journal of Pharmaceutical Sciences. The citation is as follows: 
Sueda K, Sadgrove M, Huckle JE, Leed MGD, Weber WM, Doyle-Eisele M, Guilmette RA, Jay M. Orally 
administered DTPA penta-ethyl ester for the decorporation of inhaled 
241
Am. J Pharm Sci 2014. In press. 
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a high binding affinity for 241Am with a stability constant of 1026.2 M-1, enabling it to preferentially 
bind to the radionuclide in the blood over endogenous components (6). In the absence of DTPA, 
plasma proteins and other endogenous ligands in the blood bind to 241Am and facilitate the 
migration of radionuclide to the deposition sites (23). DTPA mitigates this risk primarily by 
capturing the radionuclide prior to tissue deposition and enhancing its urinary excretion. 
As an established decorporation agent, DTPA is maintained in the United States 
Strategic National Stockpile (SNS) in case of radiological and nuclear emergencies. Its efficacy 
against 241Am contamination has been proven mostly in controlled decorporation studies with 
animal models (16;77). Rats and beagles represent the most commonly used animal models, 
and 30 µmol kg-1 has been established as the standard human dose. A single IV bolus dose of 
DTPA at 30 µmol kg-1 in rats administered 1 h after IV contamination with 241Am citrate resulted 
in the cumulative 14-day urinary decorporation of approximately 43% of the injected 241Am, 
compared to 11% in the control group (24). An analysis of the 241Am retention in bones, liver, 
and other tissues confirmed that the DTPA treatment contributed to significant reduction in 
tissue accumulation. Similar beneficial effects have been demonstrated with DTPA in beagles 
following the same weight-normalized dose. The efficacy of DTPA is also evident in humans, 
most notably in the aftermath of the Hanford americium accident (29). However, the human 
subjects were victims of accidental contamination and are not part of controlled studies; thus, 
the therapeutic effects are not fully characterized. 
Despite the supply of DTPA in the SNS, the growing concerns of nuclear terrorism and 
nuclear accidents in recent years have renewed the interest in the development of new or 
improved radionuclide decorporation agents (2). One of the major limitations of DTPA is its need 
to be administered by intravenous injection or inhalation. Such treatments require skilled 
medical personnel for administration, and in emergency situations involving mass-casualties, 
the product is not conducive to rapid distribution and self-administration. DTPA is proven to be 
most effective when the treatment commences soon after contamination; delaying the treatment 
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can significantly reduce the overall efficacy, which can only be compensated partially by 
repeated treatments over time (26;60). An orally administered dosage form can alleviate these 
limitations. However, the oral absorption of DTPA is hampered by its hydrophilic nature, 
resulting in permeability-limited absorption (32). Thus, the poor oral bioavailability of DTPA 
makes it unsuitable as a product for oral administration. 
To improve the oral delivery of DTPA, a prodrug strategy using the penta-ethyl ester 
form of DTPA is under investigation. The esterification of the ionizable carboxylic acids of DTPA 
renders a significantly more lipophilic molecule that can overcome permeability-limited 
absorption. In contrast to DTPA with a ClogP of -2.7, DTPA penta-ethyl ester has a more 
favorable ClogP of 4.7 and experimentally measured logD values of 1.5-2.5 under intestinal pH 
conditions (78). Once the prodrug overcomes the permeability barrier of the gut, it is expected 
that the carboxylic acid esters will undergo chemical and enzymatic hydrolysis to form DTPA. 
Despite the need for multiple ester cleavages, this complex prodrug is expected to be 
hydrolyzed extensively, given the prevalence of esterases along the oral absorption pathway 
(39;40;75). Moreover, prior in vivo efficacy studies have already demonstrated the absorption 
potential of this prodrug, demonstrating enhanced decorporation of 241Am in rats following 
intravenous and intramuscular contamination (48).  This work further explored the oral 
absorption potential of this prodrug by examining its pharmacokinetics and biodistribution 
following the oral administration of DTPA penta-ethyl ester. Additionally, the efficacy of this 
prodrug was investigated using the inhalation contamination model, an alternative model 
intended to mimic one of the most likely routes of contamination. 
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Materials and Methods 
Test articles 
 [14C]DTPA penta-ethyl ester was purchased from American Radiolabeled Chemicals, 
Inc. (St. Louis, MO) as a stock solution of 37 kBq µL-1 in ethanol. The 14C-labels were positioned 
on the five metabolically stable carbonyl carbon atoms of the DTPA backbone. The molecule 
possessed a specific activity of 2.04 MBq µmol-1. Non-radiolabeled DTPA penta-ethyl ester was 
synthesized using the procedure reported previously (64). 
241Am nitrate was obtained from the US Department of Energy. An aliquot of the stock 
solution was dried and reconstituted in 0.25 M nitric acid to produce a contaminating solution of 
7.4 kBq mL-1 with pH 0.74. The solution was used to create the aerosols for contaminating the 
rats in the decorporation study. 
 
Protocols for Animal Studies 
The pharmacokinetics and biodistribution studies were conducted in accordance with 
protocols approved by the Institutional Animal Care and Use Committee (IACUC) at the 
University of North Carolina at Chapel Hill. The decorporation study was approved by the 
IACUC at Lovelace Respiratory Research Institute, conducted in facilities accredited by the 
Association for Assessment and Accreditation of Laboratory Animal Care International, and 
carried out in compliance with the Guide for the Care and Use of Laboratory Animals (79). 
 
Pharmacokinetics 
 The pharmacokinetics of DTPA penta-ethyl ester and its metabolites were evaluated 
following a single, oral dose of [14C]DTPA penta-ethyl ester in female Sprague Dawley rats 
(Charles River, Morrisville, NC). Four jugular vein catheterized rats were orally administered by 
gavage with a DTPA penta-ethyl ester dose of 187 µmol kg-1 and 14.8 MBq kg-1. A mixture of 
radiolabeled and non-radiolabeled DTPA penta-ethyl ester was used to achieve these target 
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doses. The dosing solutions were prepared in a vehicle of pH 4, 25 mM citrate buffer and 
administered as a homogeneous solution at a volume of 5 mL kg-1. The rats were fasted for 6 h 
prior to dosing and housed in individual metabolic cages for the duration of the study. Food was 
presented 4 h after dosing while water was made freely accessible throughout the study. 
 The study was carried out for 24 h after administration, at which time the rats were 
euthanized. Blood and urine were collected at 1, 2, 4, 8, 12, and 24 h during the in-life phase of 
the study. Blood was obtained via the jugular vein catheters and immediately transferred to 
collection tubes containing sodium fluoride and potassium oxalate. Upon blood collection, the 
tubes were inverted several times before centrifuging at 3500 RPM for 5 min to isolate the 
plasma fraction. For assay, aliquots of plasma and urine were added directly to 10 mL of 
scintillation cocktail (Ultima Gold, Perkin Elmer, Waltham, MA) and analyzed by liquid 
scintillation counting (LSC; Tri-Carb 3110 TR, Perkin Elmer). The LSC data were corrected for 
quenching using an external standard. 
 The LSC data were used to construct profiles for plasma and urine concentrations of 14C 
during the study. Since the LSC assay cannot discriminate between the various ethyl esters of 
DTPA, all 14C-labeled molecules were treated as a single entity for the pharmacokinetic and 
urinary excretion analyses. As DTPA undergoes minimal metabolism (80), the 14C-labeled 
molecules were considered to be DTPA or its esterified form. The pharmacokinetic parameters 
were calculated by non-compartmental analysis using linear trapezoidal calculations (Phoenix 
WinNonlin, Pharsight, Cary, NC). 
 In a follow-up pharmacokinetic study, the urine composition was evaluated in an attempt 
to characterize the extent of in vivo hydrolysis of the prodrug. The study was conducted using 6 
rats with the same treatment doses as described previously. Urine samples were collected at 2, 
4, 6, 8, 12, and 24 h after oral administration, and the samples were diluted with an equal 
volume of acetonitrile immediately upon collection and stored on ice until analysis to inhibit post-
collection hydrolysis of the ester groups. During preliminary evaluations, this method was 
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determined to stabilize the esters to allow for analysis. The samples were analyzed by HPLC 
(Prominence UFLC, Shimadzu, Columbia, MD) with a flow-through radiochemical detector 
(Radiomatic 650TR, Perkin Elmer). The HPLC system was equipped with an Alltima C18 (150 × 
2.1 mm ID, 5 µm, Grace Discovery Sciences, Deerfield, IL) column operating in a 40°C oven, 
and the chromatographic separation was performed at flow rate of 0.25 mL min-1 using mobile 
phases of 0.1% trifluoroacetic acid in water (A) and 0.1% trifluoroacetic acid in acetonitrile (B). 
The mobile phase composition (A:B) followed a linear gradient from 95:5 to 5:95 over 15 min, 
followed by an isocratic phase of 5:95 for 5 min. Following the gradient separation, the eluent 
passed through the in-line radiochemical detector, where it was diluted with 5× volume of flow 
scintillation cocktail (Ultima M, Perkin Elmer). Detection and quantification occurred in a 120 µL 
flow cell using standard measurement parameters for 14C. The separation method was 
developed during preliminary work using MS detection to identify the various esters. 
 
Biodistribution 
 A biodistribution study was designed to examine the tissue distribution of 14C following 
the oral administration of [14C]DPTA penta-ethyl ester. Six female Sprague Dawley rats were 
monitored in the study using the same treatment conditions as in the pharmacokinetic studies. 
Urine and feces were collected every 4 h during the in-life phase. Euthanasia was performed 12 
h after the administration of the prodrug by overdosing with isofluorane, at which time the whole 
blood, stomach, small intestines, caecum, colon, mesentery, liver, kidneys were collected and 
weighed. Preliminary studies confirmed these to be the target organs of accumulation. The urine 
and plasma (isolated from whole blood) were processed and analyzed in the same manner as 
described above. 
The solid tissues, including feces, were diluted with a 1:1 mixture of acetonitrile and pH 
4, 25 mM citrate buffer and homogenized in polycarbonate vials containing steel grinding balls. 
The homogenization was performed by shaking the vials on the high throughput homogenizer 
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(PowerGen, Thermo Fisher Scientific, Waltham, MA) for 5-8 min at high speeds. Approximately 
200 mg of each homogenate was sampled and combined with 1 mL of Solvable (Perkin Elmer) 
and heated in an oven at 60°C for 1-3 h until digestion was visibly complete. Once the samples 
were cooled, hydrogen peroxide (30% in water) was added in two aliquots of 100 µL to de-
colorize the sample. The samples were returned to the 60°C oven for an additional 1 h. After 
cooling, each sample was diluted with 10 mL of scintillation cocktail and analyzed by LSC. The 
radioactivity measured in each sample was weight-corrected to determine the total radioactivity 
in each whole tissue. 
 
Americium decorporation 
 The treatment effects of orally administered DTPA penta-ethyl ester were evaluated by 
examining the decorporation of 241Am in F344 rats (Charles River). The rats were exposed by 
nose-only inhalation to aerosols of 241Am nitrate. The aerosols were produced with a Hospitec 
nebulizer and passed through a tube furnace to dry the particles before entering the nose-only 
small animal exposure chamber (In-Tox Products, Moriarty, NM). The administered aerosol had 
a measured 241Am concentration of 34.6 kBq L-1and particle size of 0.61 µm activity median 
aerodynamic diameter with a geometric standard deviation of 1.66 based on cascade impaction 
measurements. The animals were exposed to the aerosol for 10 min. 
A total of 21 male and 21 female rats were contaminated and divided into seven study 
groups: four treatment groups and three control groups. The treatment groups were orally 
administered by gavage with a 374 µmol kg-1 dose of DTPA penta-ethyl ester at 1 h, 1 day, 5 
days, or 14 days after 241Am contamination. The DTPA penta-ethyl ester was formulated as a 
solution in a vehicle of medium-chain triglyceride at a 20% (w/w) concentration. The dosing 
solution was administered at a volume of 1 mL kg-1. Similarly, the control groups were 
administered with 1 mL kg-1 medium-chain triglyceride vehicle at 1 day, 5 days, or 14 days after 
241Am contamination. The rats were housed in metabolic cages for the duration of the study with 
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daily urine and feces collection. Food and water were freely accessible for the duration of the 
study. 
The rats were euthanized at 7 or 8 days post-treatment and necropsy was performed to 
determine the retention of 241Am in various tissues. The lungs, trachea, tracheobronchial lymph 
nodes (TBLN), liver, spleen, kidneys, gastrointestinal tract (esophagus, stomach, upper and 
lower intestines), testes/ovaries, quadriceps muscles, femurs, and soft tissue remains were 
collected. All tissue samples, except pelt and carcass, were analyzed directly by gamma 
scintillation counting (2480 Wizard2 Gamma Counter, Perkin Elmer) for the 59.5 keV photons 
emitted by 241Am. The pelt and carcass were processed by high temperature ashing (72 h 
temperature cycles, up to 550°C) and concentrated nitric acid treatments before gamma 
scintillation counting. The 241Am retained in total muscle was calculated by measuring the 
concentration of 241Am in the quadriceps and using it to scale to total muscle. The 241Am 
concentration in the quadriceps was assumed to be representative of the total muscle, and for 
the scaling, 0.59 was used as the muscle fraction of the body mass of a rat (81). The amount of 
241Am in the total muscle was subsequently subtracted from the total 241Am recovered in carcass 
and the amount of 241Am measured in the femurs were added to determine the total 241Am 
retained in the skeleton. As the actual dose of 241Am delivered to the lungs can only be 
estimated with inhalation exposures, the amount of 241Am in each tissue was calculated as a 
fraction of the total 241Am recovered from each rat. Analyses for statistical differences to assess 
treatment effects were performed by one-way ANOVA using JMP 10.0 (SAS Institute, Cary, 
NC). 
 
Results 
Pharmacokinetics 
 Plasma and urine concentration profiles for 14C were constructed with the LSC data from 
the pharmacokinetic study. The plasma concentration profile, shown in Figure 11, exhibits an 
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absorption phase that achieves an average maximum plasma level (Tmax) at approximately 8 h 
after dosing. Even after 24 h, elevated levels of the 14C remained in the systemic circulation. 
The systemic exposure (AUC0-inf) following an oral dose of 187 µmol kg
-1 was calculated to be 
974 h nmol mL-1 by non-compartmental analysis. 
The cumulative urinary excretion profile in Figure 12 shows the excretion of 14C over the 
24 h period. The cumulative excretion over this period equates to approximately 33% of the 
administered dose. Since this quantity does not entirely account for the fraction of the dose that 
was distributed to tissues or excreted in feces, it can be assumed that the absorbed fraction is 
greater than 33%. Furthermore, from Figure 13, the AUC and urinary excretion at the same 
sampling intervals show a linear relationship (R2 = 0.877). From the slope of the linear 
regression, the renal clearance was estimated to be 0.025 L h-1, a value that is approximately 
one-third of the renal clearance of DTPA and the glomerular filtration rate in rats (53). 
A second pharmacokinetic study was conducted to characterize the extent of 
bioactivation of [14C]DTPA penta-ethyl ester by measuring the urine composition using HPLC 
with radiochemical detection. The prevalence of esterases along the oral absorption pathway 
and the absence of metabolism for DTPA suggest that any in vivo modifications to the prodrug 
should be associated with the hydrolysis of the ester groups. The various DTPA esters that 
were measured in the urine are summarized in Figure 14. The chromatographic analysis of the 
urine revealed the complete metabolism of the penta-ester form as none was detected. 
Likewise, the tetra-ester form was also not detectable in urine. The analysis revealed that the 
bioactivation of DTPA penta-ethyl ester was extensive but incomplete. DTPA tri-ethyl ester 
represented the most abundant intermediate at all time points, and DTPA was the second most 
abundant. After 24 h, DTPA tri-ethyl ester and DTPA made up 33% and 30% of the total 14C in 
urine, respectively. These corresponded to 11% and 10% of the administered prodrug dose, 
respectively. The mono- and di-ester forms collectively accounted for the remaining third of the 
14C detected in urine. 
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Biodistribution 
 The tissue distribution of 14C was assessed 12 h following the oral administration of 
[14C]DTPA penta-ethyl ester. The results are summarized in Table 8. Tissue analysis 
determined that approximately 73% of the administered 14C was associated with the 
gastrointestinal tract after 12 h. Of this, 29% was found to be associated with the stomach, 
suggesting that prolonged gastric retention or gastric secretion may have contributed to 
incomplete absorption. The slow release of the prodrug from the stomach may have contributed 
to a prolonged duration of absorption, resulting in the sustained plasma profile that was 
observed in the pharmacokinetic study. In addition to the stomach, high levels of 14C were 
measured in the caecum and colon, representing approximately 22% and 18% of the 
administered dose, respectively. Interestingly, despite the high levels in the stomach and colon, 
the small intestine contained the lowest levels along the gastrointestinal tract, accounting for 
only 3% of the administered dose. Meanwhile, fecal excretion was negligible. 
Of the tissues that do not make up the gastrointestinal tract, the liver exhibited the 
highest 14C content. However, it contained less than 1% of the administered dose. 
Approximately 20% of the administered dose was excreted in the urine, consistent with 
cumulative recovery at 12 h from the pharmacokinetic study. Despite the high excretion of 14C in 
the urine, the kidney contained negligible amounts. Collectively, a total of 90-110% of the 
administered 14C was recovered from each rat. This suggests that negligible amounts of DTPA 
penta-ethyl ester and its hydrolysis products distributed to the remainder of the carcass. 
 
Decorporation 
 Significant therapeutic effects were observed in rats treated with orally administered 
DTPA penta-ethyl ester following inhalation exposure to 241Am. The tissue distribution of 241Am 
following the various treatments is provided in Table 9. The treatment groups recovered 21.7-
24.6 kBq of total 241Am from individual rats, and these recovery values were used to determine 
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the fraction of 241Am that were retained in the various tissues. Comparison of the DTPA penta-
ethyl ester treatment groups to the corresponding control groups revealed that the prodrug 
significantly reduced the accumulation of 241Am in certain tissues. This decorporation effect was 
particularly evident in the liver, lungs, and bone, tissues that are known to be associated with 
241Am accumulation. In the case of a 1-hour delay, the improvements corresponded to 11- and 
4-fold reduction in the liver and lungs, respectively (p < 0.01). At least 2-fold reductions were 
observed in the bone, gastrointestinal tract, kidneys, muscle, soft tissues, and spleen (p < 0.05). 
Moreover, the treatment was most effective when the treatment delays were minimized. The 
apparent high fecal excretion in all treatment groups was attributed to the mucociliary clearance 
of 241Am as a consequence of the inhalation delivery. 
The effects of DTPA penta-ethyl ester in promoting the excretion of 241Am were also 
clearly evident in the urine data. The daily urinary excretion profiles in Figure 15 show the 
effects of the prodrug when the treatment was administered 1 h after contamination. The 
treatment effects were most prominent during the first 3 days after treatment. During this period, 
the prodrug facilitated the excretion of nearly 18% of the inhaled 241Am, representing nearly 96% 
of the cumulative excreted total. Over the 8-day duration, a total of 19% of the inhaled 241Am 
was excreted, corresponding to a nearly 30-fold improvement compared to the control (p 
< 0.001). When treatment delays were extended, the overall decorporation effects were 
reduced. The effects of treatment delay on decorporation appear in the cumulative excretion 
profiles of Figure 16. The profiles show that a 2-week delay in treatment reduced the cumulative 
excretion of 241Am by approximately 5-fold compared to a 1-hour delay (p < 0.001). Even so, the 
treatment facilitated the total decorporation of approximately 4% of the inhaled 241Am, a 
significant improvement over the control (p < 0.01). The prodrug was most effective when the 
treatment delays were minimized, consistent with observations previously reported for DTPA. 
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Discussion 
In order to overcome the oral delivery challenges of DTPA, the penta-ethyl ester prodrug 
of DTPA was designed with the intent to increase the lipophilicity of DTPA. Previously reported 
physicochemical properties of this prodrug revealed that it has significantly higher lipophilicity 
than DTPA and thus, promising potential for oral delivery (78). The in vivo studies of this work 
confirmed this absorption potential, demonstrating that at least 33% of the administered dose 
was orally absorbed over 24 h based on the urinary excretion data alone. The extent of 
absorption is significantly higher than orally administered DTPA, which has a reported 
bioavailability of 3% (32). 
The improved oral delivery potential with DTPA penta-ethyl ester is further evident when 
the pharmacokinetic parameters of the prodrug and DTPA are compared. Following an oral, 187 
µmol kg-1 dose of the prodrug, DTPA penta-ethyl ester and its hydrolysis products contributed to 
an AUC0-inf and renal clearance of 974 h nmol mL
-1 and 0.025 L h-1, respectively. In contrast, 
intravenously administered DTPA at a dose of 29.4 µmol kg-1 resulted in an AUC0-inf and 
clearance of 7.1 h nmol mL-1 and 0.25 L h-1, respectively (47). Even with dose-normalization to 
account for the difference in administered doses, the prodrug exhibited 20-fold higher exposure 
and a 10-fold lower clearance than DTPA. The significant difference in these pharmacokinetic 
parameters suggests that the pharmacological activity of the prodrug treatment is likely to be 
significantly different from DTPA. 
While the rate and extent of bioactivation of DTPA penta-ethyl ester remains unknown, 
the pharmacokinetic behavior following the administration of this prodrug could be favorable for 
improving the radionuclide decorporation effects over DTPA. One limitation of DTPA for 
therapeutic efficacy may be its rapid elimination kinetics in relation to the biokinetics of 
radionuclides. The primary site of DTPA chelation is in the blood and extracellular fluid (ECF), 
and while the rapid onset and elimination following a bolus injection of DTPA may be 
advantageous for facilitating the rapid excretion of contaminants, the chelating agent must be 
59 
 
present in the blood and ECF at the appropriate time and at sufficient levels to intercept the 
contaminant. Thus, it is important for the pharmacokinetics of DTPA to align with the biokinetics 
of the contaminant. However, not all contamination scenarios manifest themselves in immediate 
uptake of the contaminant into the systemic circulation. The rate of systemic entry depends on 
the route of contamination and the properties of the radionuclide, including solubility, charge, 
and chemical form (4;54). Inhalation and wound uptake are considered to be two of the most 
probable routes of radionuclide contamination and are characterized as exhibiting slow or 
protracted entry of the contaminant into the bloodstream (31;77;82). Unless frequent injections 
or continuous infusion of DTPA are administered, its rapid elimination will quickly deplete the 
available DTPA in the blood and allow for only a limited duration of efficacy. Accordingly, 
alternative delivery methods for both DTPA and DTPA penta-ethyl ester have been proposed 
(25;32;45;54;83-86). An orally bioavailable chelating agent that can provide extended durations 
of efficacy may be better suited for radionuclide decorporation in a real life contamination 
scenario. 
Interestingly, the plasma concentration of 14C following the oral administration of 
[14C]DTPA penta-ethyl ester appears to exhibit a sustained profile. The long residence time of 
the prodrug and its DTPA intermediates in the plasma is in stark contrast to DTPA, which is 
known to be eliminated very rapidly with a half life of 0.53 h following an intravenous injection 
(47). A possible explanation for the sustained profile is that the prodrug is absorbed over an 
extended duration contributing to a prolonged influx of 14C into the systemic circulation. Based 
on the high retention of 14C in the stomach from the biodistribution study, the stomach may be 
acting as a depot. Previous in vitro evaluations suggested that the prodrug is sufficiently stable 
against premature chemical hydrolysis in the acidic environment of the stomach (48). 
Alternatively, the prodrug may be metabolized in the epithelium, entrapping the DTPA 
intermediates and slowing its transport to the systemic circulation. Another possibility for the 
sustained plasma levels may be the result of altered elimination kinetics, a potential 
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consequence of the incomplete conversion of DTPA penta-ethyl ester to DTPA in the plasma. 
The DTPA intermediates are more lipophilic than DTPA and may have a higher tendency to 
bind to plasma proteins resulting in lower renal clearance. The intermediates may also distribute 
more readily to the tissues, further reducing the elimination rate. The combination of longer 
absorption, larger volumes of distribution and slower elimination may contribute to producing a 
sustained plasma concentration profile as the one observed with the prodrug treatment. 
An analysis of the urine composition confirmed that the bioactivation of DTPA penta-
ethyl ester was extensive but incomplete. Preliminary in vitro stability evaluations of DTPA 
penta-ethyl ester in rat plasma revealed that hydrolysis is very rapid, with complete loss of the 
penta- and tetra-ester forms occurring within 10 min (data not shown). Thus, it was considered 
improbable for any absorbed prodrug to enter the plasma and avoid metabolism before 
excretion. Unfortunately, an attempt to characterize the composition in plasma was 
unsuccessful. As part of the pharmacokinetic study, plasma samples were diluted with 
acetonitrile and analyzed by HPLC using the same methods as described for urine. This sample 
processing method appeared to sufficiently stabilize the DTPA esters during preliminary in vitro 
evaluations; however, the data from the in vivo study indicated a nearly complete conversion to 
DTPA. Since the in vivo study required additional time to isolate the plasma from whole blood 
before the sample could be stabilized, it is believed that the multi-ester intermediates may have 
hydrolyzed during this period. Under these circumstances, the composition in the urine was 
considered to provide the most reliable representation of the extent of bioactivation. 
Despite the incomplete bioactivation of DTPA penta-ethyl ester to DTPA, the in vivo 
decorporation study demonstrated the therapeutic potential of the prodrug. The inhalation route 
of contamination was chosen in this decorporation study to mimic the route of contamination 
that may occur in a real-life scenario. Contamination with 241Am nitrate is a realistic hazard and 
the chemical complex is a moderately soluble form that can slowly release from the lung and 
into the systemic circulation (17;77;81). Administering the prodrug 1 h after contamination 
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resulted in an 11-fold decrease in liver accumulation compared to the control in this study. 
However, as previously reported, administering the same treatment with the same treatment 
delay after intravenous and intramuscular contamination reduced the accumulation of 241Am in 
liver by less than 3-fold compared to the corresponding controls (48). Although the extent of 
actual decorporation may differ due to differences in the amount of accessible contaminant, the 
relative therapeutic effects in the context of the corresponding controls emphasize the 
importance of understanding the distribution kinetics of the contaminant to select the 
appropriate type of treatment. 
The observed efficacy in spite of the incomplete hydrolysis of DTPA penta-ethyl ester 
seen in urine suggests that the overall decorporation may be an additive effect produced by the 
contributions from the various DTPA intermediates. Even with incomplete bioactivation, the 
DTPA intermediates possess multiple coordination sites to chelate metals in the blood. This 
potential is exemplified in the established relationship between the number of coordination sites 
on a chelating agent and the binding of 241Am (19). The tri-ethyl ester of DTPA, with five 
coordination sites, represents the DTPA intermediate in the urine with the fewest number of 
coordination sites. According to this relationship, it may still possess a high affinity for 241Am with 
a stability constant of approximately 1015 M-1. The other intermediates have a greater number of 
coordination sites and would likely have greater affinities for 241Am. Assuming that this 
relationship applies for all DTPA intermediates, complete bioactivation of DTPA penta-ethyl 
ester to DTPA may not be necessary to effectively chelate 241Am in the blood. 
In addition to intercepting the radionuclides in the blood, extraction of contaminants from 
tissues is another means to facilitate decorporation. However, the conventional DTPA treatment 
is challenged by its limited ability to cross cell membranes and facilitate the excretion of 
contaminants from the intracellular compartment of tissues (45). A complete conversion of 
DTPA penta-ethyl ester to DTPA may not be favorable to facilitate the removal of deposited 
radionuclides. Partially hydrolyzed forms of the prodrug are more lipophilic than DTPA and may 
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have the potential advantage to access the intracellular space, thereby enhancing the extraction 
of radionuclides from the deposition sites. The penta-ethyl ester of DTPA was previously 
administered by intraperitoneal injection to explore this decorporation mechanism and was 
proven to facilitate intracellular decorporation of 239Pu (45). This type of mechanism may be 
particularly advantageous when the treatment following contamination is delayed and extensive 
tissue deposition has already occurred. This effect appears to be evident in the decorporation 
study reported here which showed that the 241Am retention in the primary deposition sites of 
lung, liver, and bone were reduced significantly even after a 14-day delay in the treatment with 
the prodrug. With an intracellular decorporation mechanism, repeated administration of this 
prodrug may further add to the therapeutic effects by extending the ability to extract the 
radioactive contaminants from the deposition sites. 
The DTPA penta-ethyl ester treatments were most efficacious when the treatment 
delays after contamination were minimized. An extension of the treatment delay from 1 h to 1 
day resulted in a 2-fold reduction in 241Am decorporation. The decrease in the therapeutic effect 
became less apparent with longer treatment delays. This overall trend is consistent with the 
effects observed after conventional DTPA treatments, which relies primarily on intercepting the 
radionuclides before tissue deposition. Even though the incomplete bioactivation of the prodrug 
may enhance the intracellular decorporation of radionuclides, capturing the contaminants before 
deposition appears to be the most effective mechanism for decorporation. The diminished 
effects after longer treatment delays with this prodrug reflect the need to still provide urgent 
treatment to victims of contamination. 
 
Conclusion 
The pharmacokinetics, biodistribution and efficacy of orally administered DTPA penta-
ethyl ester were investigated in rats. A single dose treatment in the pharmacokinetics study 
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revealed that greater than 33% of the administered dose was absorbed based on urinary 
excretion data alone. From the urine composition, the bioactivation was determined to be 
extensive but incomplete. The plasma concentration profile showed elevated plasma levels of 
the prodrug and its hydrolysis products for 24 h. The biodistribution study showed that the 
prodrug and the intermediates were primarily retained in the gastrointestinal tract with limited 
distribution to other tissues after 12 h. In the efficacy study, a single dose treatment of DTPA 
penta-ethyl ester administered after contamination enhanced the decorporation of inhaled 241Am 
by as much as 15-fold compared to the control. Consistent with prior reports of DTPA, the 
therapeutic effects of the prodrug were maximized when the treatment delays were minimized. 
Overall, DTPA penta-ethyl ester exhibited promising pharmacokinetic and therapeutic behavior 
as an orally administered radionuclide decorporation agent.  
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Tables 
Table 8 Tissue distribution of 14C from the PO administration of [14C]DTPA prodrug 
Tissue distribution of 14C in rats at 12 h following the oral administration of 187 µmol kg-1 DTPA 
penta-ethyl ester; data expressed as mean ± 95% CI 
Tissue 14C (% of administered) 
Caecum 22.2 ± 8.7 
Colon 18.5 ± 7.1 
Feces 0.68 ± 1.13 
Kidneys 0.147 ± 0.057 
Liver 0.759 ± 0.152 
Mesentery 0.039 ± 0.008 
Small intestines 3.33 ± 0.94 
Spleen 0.010 ± 0.007 
Stomach 28.9 ± 10.5 
Urine 20.5 ± 5.1 
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Table 9 Tissue distribution of 241Am after treatment with DTPA penta-ethyl ester 
Tissue distribution of inhaled 241Am in rats after various treatment delays with orally 
administered 374 µmol kg-1 DTPA penta-ethyl ester; data expressed as mean ± 95% CI; 
statistical significance of the prodrug treatment compared to control: * p < 0.05, ** p < 0.01, *** p < 0.001 
Tissue 
241Am Recovery  by Treatment Type 
Control, 
1 d delay 
Prodrug, 
1 h delay 
Prodrug, 
1 d delay 
Control, 
5 d delay 
Prodrug, 
5 d delay 
Control, 
14 d delay 
Prodrug, 
14 d delay 
Blood 
0.000 
± 0.000 
0.000 
± 0.000 
0.001 
± 0.001 
0.000 
± 0.000 
0.000 
± 0.000 
0.000 
± 0.000 
0.000 
± 0.000 
Bone 
4.80 
± 2.01 
2.10** 
± 0.16 
2.86* 
± 0.68 
5.72 
± 1.57 
3.92* 
± 0.50 
6.18 
± 1.56 
5.19 
± 1.29 
Feces 
71.6 
± 10.7 
72.6 
± 5.3 
77.4 
± 2.4 
73.5 
± 5.5 
78.2 
± 3.62 
79.1 
± 4.6 
81.7 
± 3.1 
GI tract 
1.17 
± 0.42 
0.450** 
± 0.086 
0.832 
± 0.215 
1.12 
± 0.21 
0.636*** 
± 0.109 
0.741 
± 0.184 
0.575 
± 0.115 
Kidneys 
0.607 
± 0.231 
0.219** 
± 0.065 
0.353* 
± 0.20 
0.708 
± 0.249 
0.523 
± 0.152 
0.650 
± 0.243 
0.547 
± 0.144 
Liver 
7.65 
± 3.95 
0.693** 
± 0.253 
1.59** 
± 1.14 
7.32 
± 2.69 
2.94** 
± 1.30 
5.37 
± 1.78 
3.21 
± 2.06 
Lungs 
10.1 
± 3.5 
2.47** 
± 0.36 
4.55** 
± 1.29 
8.44 
± 1.24 
4.63*** 
± 0.89 
5.34 
± 1.32 
3.75* 
± 0.59 
Muscle 
0.469 
± 0.332 
0.165* 
± 0.053 
0.332 
± 0.064 
0.561 
± 0.111 
0.362** 
± 0.102 
0.460 
± 0.130 
0.416 
± 0.059 
Ovaries 
0.006 
± 0.005 
0.002 
± 0.002 
0.004 
± 0.001 
0.006 
± 0.004 
0.003 
± 0.003 
0.005 
± 0.004 
0.005 
± 0.002 
Pelt 
2.71 
± 1.57 
2.02 
± 0.70 
3.15 
± 1.32 
1.47 
± 0.40 
1.30 
± 0.56 
0.748 
± 0.105 
0.660 
± 0.170 
Soft tissue 
0.160 
± 0.053 
0.052** 
± 0.016 
0.093* 
± 0.025 
0.167 
± 0.096 
0.151 
± 0.082 
0.171 
± 0.051 
0.138 
± 0.051 
Spleen 
0.020 
± 0.010 
0.007** 
± 0.001 
0.014 
± 0.005 
0.026 
± 0.006 
0.025 
± 0.011 
0.029 
± 0.008 
0.039 
± 0.013 
TBLN 
0.001 
± 0.004 
0.001 
± 0.001 
0.001 
± 0.001 
0.004 
± 0.002 
0.002 
± 0.002 
0.001 
± 0.001 
0.001 
± 0.001 
Testes 
0.019 
± 0.017 
0.008 
± 0.007 
0.011 
± 0.004 
0.025 
± 0.008 
0.020 
± 0.004 
0.027 
± 0.029 
0.022 
± 0.016 
Urine 
0.651 
± 0.194 
19.2*** 
± 5.2 
8.80*** 
± 2.09 
0.942 
± 0.324 
7.34*** 
± 2.49 
1.19  
± 0.12 
3.73*** 
± 1.30 
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Figures 
 
Figure 11 Plasma concentration of 14C from the PO administration of [14C]DTPA prodrug 
Plasma concentration profile of 14C in rats after the PO administration of 187 µmol kg-1 DTPA 
penta-ethyl ester; data expressed as profiles for individual rats 
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Figure 12 Urinary excretion of 14C from the PO administration of [14C]DTPA prodrug 
Urinary excretion profile of 14C in rats after the PO administration of 187 µmol kg-1 DTPA penta-
ethyl ester; data expressed as profiles for individual rats 
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Figure 13 Systemic exposure and urinary excretion of 14C within sampling intervals from the 
PO administration of [14C]DTPA prodrug  
Correlation of AUC and urinary excretion of 14C within the same sampling intervals from the PO 
administration of 187 µmol kg-1 DTPA penta-ethyl ester in rats 
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Figure 14 Urine composition from the PO administration of DTPA penta-ethyl ester 
Composition of DTPA penta-ethyl ester and its bioactivation intermediates in urine of rats after 
the PO administration of187 µmol kg-1 DTPA penta-ethyl ester 
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Figure 15 Daily urinary excretion of 241Am after a 1-hour treatment delay 
Effect of orally administered 374 µmol kg-1 DTPA penta-ethyl ester on the daily urinary excretion 
of inhaled 241Am in rats following a 1-hour treatment delay 
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Figure 16 Cumulative urinary excretion of 241Am by treatment groups 
Effect of delaying treatment with orally administered 374 µmol kg-1 DTPA penta-ethyl ester on 
the cumulative urinary excretion of inhaled 241Am in rats; statistical difference between treatment 
groups determined on the cumulative total: * p < 0.05, ** p < 0.01, *** p < 0.001
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CHAPTER 5: SUMMARY 
 
The in vitro competitive binding studies in plasma identified important species 
differences in the effective concentration of DTPA for 241Am chelation. From the dose-response 
curves for DTPA, the EC90 values were determined to be 31.4, 15.9, and 10.0 µM in rat, beagle, 
and human plasma, respectively. These values correspond to plasma concentrations of DTPA 
that maximize 241Am chelation while minimizing excess DTPA. Furthermore, these species 
differences may have implications on the effective duration of DTPA as a result of the 
differences in the pharmacokinetic behavior of DTPA in the different species. Based on the 
pharmacokinetic profile of DTPA in humans after a standard 30 µmol kg-1 intravenous bolus 
injection, the plasma concentration of DTPA remains above EC90 for approximately 5.6 h. 
Likewise with same weight-normalized dose of DTPA, the effective duration of DTPA in rat and 
beagle were determined to be 0.67 and 1.7 h, respectively. These results suggest that species 
differences must be considered when translating the efficacy data of DTPA from animals to 
humans. Since animal models were essentially used to establish the standard therapeutic doses 
for humans, these findings offer insight into opportunities to improve the current dosing regimen 
for DTPA. Ultimately, these differences may be useful to support the development of alternative 
DTPA products under the FDA Animal Rule. 
The implementation of a prodrug strategy using DTPA penta-ethyl ester demonstrated 
promising potential. The in vitro characterization of DTPA penta-ethyl ester revealed 
physicochemical properties that are favorable for oral delivery. DTPA penta-ethyl ester was 
determined to be a low viscosity liquid with Newtonian flow characteristics. Consistent with the 
measured pKa values, which range from 2.93 to 10.87, the prodrug exhibits pH-dependent 
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solubility and lipophilicity properties that are representative of a weak base and favorable for 
oral absorption. It is miscible in solvents that are non-polar to moderately polar and is sufficiently 
stable to avoid premature hydrolysis during gastrointestinal transit. Caco-2 permeability assays 
confirmed the improved transport potential of the prodrug over DTPA. Therapeutic effects were 
demonstrated in an initial efficacy study where oral treatments of the prodrug were given to rats 
contaminated with 241Am by intravenous injection, providing preliminary indications of successful 
oral delivery. The properties of the prodrug indicate that it is conducive to oral delivery and may 
offer therapeutic benefits over the standard DTPA therapy following radionuclide contamination. 
To further explore the oral delivery potential, pharmacokinetic and biodistribution studies 
were conducted in rats using [14C]DTPA penta-ethyl ester. Due to the challenges of 
characterizing the metabolic activation process for this complex prodrug, DTPA penta-ethyl 
ester and its hydrolysis products were analyzed as a single entity in these studies. A single dose 
oral administration of the prodrug showed a sustained plasma concentration profile of 14C with 
20-fold higher exposure and a 10-fold lower clearance than intravenously administered DTPA 
under dose-normalized conditions. Approximately 33% of the administered dose was excreted 
in urine over 24 h. An assessment of the composition in urine revealed that the bioactivation 
was incomplete but extensive, with no detectable levels of the penta- or tetra-ethyl ester forms 
of DTPA. The tissue distribution of 14C after 12 h was limited, with less than 1% of the 
administered dose in the liver and kidneys and approximately 73% associated with the 
gastrointestinal tract. Approximately 24% of the 14C was excreted in feces after 24 h from the 
intravenous administration of [14C]DTPA penta-ethyl ester, which suggests that biliary clearance 
contributed to the large quantity of 14C that was found in the lower gastrointestinal tract from the 
biodistribution study. 
In the decorporation study, rats were exposed to aerosols of 241Am nitrate before 
receiving a single dose oral treatment of DTPA penta-ethyl ester. The study revealed that as 
much as 19% of the contaminants could be excreted in urine with the prodrug treatment, 
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compared to only 1% with a placebo treatment. Consistent with prior reports of DTPA, the 
prodrug treatment was most effective when the treatment delays were minimized, reflecting the 
importance of providing immediate treatment after contamination. Overall, the therapeutic 
effects demonstrated that the prodrug can be delivered orally to achieve plasma levels that are 
sufficient to facilitate the decorporation of 241Am. 
Characterizing the biotransformation of DTPA penta-ethyl ester is a necessary step to 
understanding of the mechanisms involved in the drug delivery and efficacy of this prodrug. 
DTPA penta-ethyl ester is a complex prodrug that requires multiple hydrolysis steps to convert 
fully to DTPA. In addition to the sheer number of ester cleavages, various compartments along 
the oral absorption pathway may contribute to the bioactivation of this prodrug; thus, 
establishing an understanding of the rate and extent of the in vivo hydrolysis of this prodrug may 
prove to be a difficult challenge. Nonetheless, it is proposed that future efforts be focused on 
establishing an understanding of the processes involved in the bioactivation of this prodrug. 
Additionally, determining the chelation potential of each DTPA intermediate could 
provide valuable insight into the mechanism of decorporation associated with orally 
administered DTPA penta-ethyl ester. The pharmacokinetic study demonstrated that the 
bioactivation of DTPA penta-ethyl ester to DTPA is incomplete and yet, significant decorporation 
effects were observed. Based on its high binding affinity for metals, DTPA is presumably the 
most therapeutically active form; however, the DTPA intermediates possess multiple 
coordination sites and are likely to also participate in metal complexation. Moreover, while the 
decorporation effects of DTPA are primarily limited to the extracellular fluids, it may be possible 
for the more lipophilic intermediates to facilitate decorporation from locations that are 
inaccessible by DTPA. In combination with elucidating the biotransformation of DTPA penta-
ethyl ester, an understanding of the chelation behavior of the intermediates could contribute to a 
mechanistic understanding of the decorporation effects that were demonstrated with this 
prodrug.
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APPENDIX 1: CACO-2 PERMEABILITY OF DTPA PENTA-ETHYL ESTER 
 
Introduction 
 Caco-2 cells are human colon adenocarcinoma cells that are commonly used for in vitro 
permeability assays to evaluate the intestinal absorption potential of drugs. When the cells are 
cultured in a monolayer, they resemble the morphology and functionality of intestinal epithelial 
lining (87-89). Structurally, they arrange into polarized units with microvilli that resemble the 
brush border region of enterocytes and form tight junctions between cells. Functionally, they 
express various transport proteins, including efflux transporters, and Phase II conjugation 
enzymes that are found in the enterocytes of the small intestine. This cell-based assay serves 
as an important tool in drug development for its ability to model the paracellular and transcellular 
transport pathways. 
The physicochemical properties of DTPA penta-ethyl ester summarized in Chapter 2 
suggest that the prodrug is favorable for oral delivery. To supplement the in vitro 
characterization and further evaluate its oral absorption potential, permeability assays were 
conducted in the Caco-2 cell monolayer system. 
 
Methods 
The transport experiments were conducted to compare the permeability of [14C]DTPA 
and [14C]DTPA penta-ethyl ester across Caco-2 cell monolayers. The permeability of 
[14C]mannitol, a marker for paracellular transport, was also determined in parallel. The 
[14C]DTPA penta-ethyl ester was purchase from American Radiolabeled Chemicals (St. Louis, 
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MO) as a stock solution in ethanol containing 50 mCi mmol-1. The 14C-labels were positioned on 
the five metabolically stable carbonyl carbon atoms of the DTPA backbone. The [14C]DTPA was 
converted from the [14C]DTPA penta-ethyl ester by adding concentrated sodium hydroxide and 
subsequently adding equimolar amount of hydrochloric acid to neutralize the solution. The 
[14C]mannitol was obtained from Moravek (Brea, CA) as a solution of 55 mCi mmol-1. The Caco-
2 cell line originated from American Type Culture Collection (Manassas, VA). 
The Caco-2 cells were cultured using a method developed previously (90). The cell 
culture medium comprised of Eagle’s minimum essential medium (with Earle’s salts and L-
glutamate) supplemented with 10% fetal bovine serum, 1% non-essential amino acids, 100 units 
mL-1 penicillin, 100 µg mL-1 streptomycin, and 0.25 µg mL-1 amphotericin B (Life Technologies, 
Grand Island, NY). During incubation, the cells were stored at 37°C in an atmosphere of 5% 
CO2 and 95% relative humidity. Cell passaging was performed with trypsin-EDTA, and cells of 
passages 41-42 were seeded at a density of approximately 60,000 cells cm-2 on 12 mm 
diameter Transwell inserts with polycarbonate membranes of 0.4 µm pore size (Corning, 
Tewksbury, MA). The medium was changed every 2-3 days and the transport experiments were 
conducted within 5 weeks of seeding. 
Prior to the start of the transport experiments, the culture medium was replaced with 
transport medium. The transport medium was a pH 7.2 aqueous buffer comprised of Hank’s 
Balanced Salt Solution (with calcium and magnesium) with 25 mM glucose and 10 mM N-
hydroxyethylpiperazine-N-2-ethanesulfonate (HEPES). After initial washing of the culture plates 
with the transport medium, the trans-epithelial electrical resistance (TEER) was measured using 
EVOM2 Epithelial Voltohmmeter with STX3 Chopstick Electrode (World Precision Instruments, 
Sarasota, FL) to verify integrity of the monolayers. Only the inserts with TEER values greater 
than 300 Ω × cm2 were used. 
The transport experiments were initiated by filling the basolateral compartment with 1.5 
mL of transport medium and the apical compartment with 0.5 mL of transport medium 
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containing the test material. The medium on the basolateral side was sampled every 20 or 30 
minutes for assay and the experimental runs were carried out for up to 1.5 h. Sink conditions 
were maintained by transferring the inserts to new cell culture plates containing fresh transport 
medium on the basolateral side at the sampling times. Each experimental condition was 
performed in triplicate using individual Transwell inserts. At the end of the experiment, the 
medium on the apical side was also sampled and assayed. The collected samples were 
analyzed for 14C content by both liquid scintillation counting (LSC) and HPLC. 
The total 14C activity in each sample was measured by LSC using the Tri-Carb 3110 TR 
(Perkin Elmer). The samples were prepared for analysis by diluting the sample aliquots in 10 mL 
of Ultima Gold scintillation cocktail (Perkin Elmer). The measurements were conducted using 
standard measurement parameters for 14C activity. The LSC data were corrected for quenching 
using an external standard. LSC was used to measure the transport of all radio-labeled 
molecules across the cell monolayer, and the permeability coefficients were calculated with the 
LSC data using standard flux equations. 
HPLC was used to determine the relative fraction of the various DTPA intermediates that 
were present in each sample. The sample aliquots were diluted immediately with equivalent 
portion of acetonitrile at the time of collection to inhibit ester hydrolysis. HPLC analysis was 
performed with the Shimadzu Prominence HPLC equipped with the Alltima C18 column (250 
mm × 2.1 mm ID, 5 µm) and the Radiomatic 625TR Flow Scintillation Analyzer (Perkin Elmer). 
The reverse phase gradient separation was performed with a column temperature of 40°C, a 
flow rate of 0.2 mL min-1, and mobile phases of water with 0.1% trifluoroacetic acid (A) and 
acetonitrile (B). The mobile phase composition (A:B) followed a linear gradient from 95:5 to 5:95 
over 20 min, followed by an isocratic phase of 5:95 for 8 min. The radiomatic detection was 
performed using a 125 μL flow cell with UlitmaFlo M (Perkin Elmer) scintillation cocktail at a flow 
rate of 1.0 mL min-1. Standard detection parameters for the measurement of 14C were utilized. 
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Results 
Transport experiments were conducted in the Caco-2 cell monolayer system to compare 
the permeability of DTPA and DTPA penta-ethyl ester. The results are provided in Table 10. 
Consistent with its high charge density and low lipophilicity, DTPA exhibited poor transport 
behavior with a low permeability coefficient of 1.52 × 10-7 cm s-1. At a concentration of 76 µM, 
the flux was measured to be 0.694 pmol min-1 cm-1. In contrast, a significantly higher 
permeability coefficient of 1.85 × 10-5 cm s-1 was measured with DTPA penta-ethyl ester. 
Despite the use of a lower input concentration of 49 µM, a significantly higher transport flux of 
54.4 pmol min-1 cm-1 was observed. Approximately 23% of the input 14C crossed the cell 
monolayer and approximately 67% remained in the apical compartment after 1.5 h, suggesting 
that approximately 10% of the input 14C were retained in the intracellular compartment. The 
measured permeability coefficient of mannitol of 7.2 × 10-7 cm s-1 was consistent with previously 
reported literature values, confirming the integrity of the cell monolayer. 
Additional conditions with DTPA penta-ethyl ester were also explored to evaluate the 
effect of input concentration on flux.  Using starting concentrations of approximately 50, 100, 
and 150 µM in the apical compartment, the flux was determined to be directly proportional to the 
input concentration, as shown in Figure 17. The linearity demonstrated over this concentration 
range suggests that the transport mechanism was not saturated and confirms the suitability of 
these conditions for measuring the permeability coefficient of DTPA penta-ethyl ester. 
While the LSC data revealed extensive transport of the 14C, the HPLC analysis revealed that the 
hydrolysis of DTPA penta-ethyl ester after transport was far from complete. The composition of 
the bioactivation intermediates found in the receiver compartment appears in Figure 18. DTPA 
penta-ethyl ester and DTPA tetra-ethyl ester were the main constituents found in the receiver 
compartment after 1.5 h, accounting for approximately 8.6 and 10.3%, respectively, of the input 
DTPA penta-ethyl ester. More importantly, DTPA was recovered in the receiver compartment as 
only 3% of the input DTPA penta-ethyl ester. These results suggest that DTPA penta-ethyl ester 
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may require additional mechanisms of bioactivation beyond the metabolic capabilities of the gut 
wall to deliver DTPA extensively to the systemic circulation. 
 
Discussion 
The use of Caco-2 cell permeability data to predict oral absorption has been well-
documented (86-88), and the transport studies suggest that DTPA penta-ethyl ester has 
significantly improved oral absorption potential over DTPA. DTPA exhibited low Caco-2 cell 
permeability, indicative of low oral absorption potential, which is also consistent with prior 
reports of the low bioavailability observed in in vivo studies. In contrast, DTPA penta-ethyl ester 
exhibited high permeability and from the correlation models to predict absorption (88), 
absorption of greater than 75% may be expected. These results were consistent with the 
expectations for DTPA penta-ethyl ester based on its physicochemical properties reported in 
Chapter 2. 
An advantage of using cell-based membranes over artificial membranes for transport 
studies is that the Caco-2 cells possess active enzymes and transporters, creating a more 
representative model for estimating oral absorption. Such an understanding is even more 
important in the case of prodrugs, such as DTPA penta-ethyl ester, that require enzymatic 
activation for therapeutic activity. In the case of DTPA penta-ethyl ester, the bioactivation during 
the transport across Caco-2 cells was far from complete, which suggest that additional 
hydrolysis mechanisms will be required to cleave the remaining ester moieties after uptake. 
Fortunately, the high activity of esterases in the plasma and hepatocytes should be favorable to 
advance the conversion of DTPA penta-ethyl ester to DTPA. However, it is also important to 
note that while Caco-2 cells can be useful as an in vitro tool for assessing the bioactivation of  
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prodrugs during intestinal transport, they do not accurately mimic the esterase expression levels 
of the small intestines and must be used carefully, particularly in the case of ester- and amide-
containing prodrugs (91;92).  
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Tables 
Table 10 Transport flux and permeability in Caco-2 cells 
Test article 
Concentration 
(µM) 
Flux 
(pmol min-1 cm-1) 
Papp 
(× 10-7 cm s-1) 
Mannitol 3.6 0.119 ± 0.022 7.16 ± 0.13 
DTPA 76 0.694 ± 0.069 1.52 ± 0.16 
DTPA penta-ethyl ester 49 54.4 ± 5.4 185 ± 18 
Data expressed as mean ± 95% CI 
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Figures 
 
Figure 17 Effect of DTPA penta-ethyl ester concentration on transport flux in Caco-2 cells 
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Figure 18 Composition of DTPA esters in the receiver compartment 
Composition of DTPA penta-ethyl ester and its bioactivation intermediates found in the receiver 
compartment during Caco-2 permeability assay 
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APPENDIX 2: INTRAVENOUS ADMINISTRATION OF DTPA PENTA-ETHYL ESTER 
 
Introduction 
 The pharmacokinetic studies conducted with the oral administration of DTPA penta-ethyl 
ester revealed significant absorption of the prodrug with sustained plasma levels. To provide 
further insight into the disposition of DTPA penta-ethyl ester and its intermediates, a 
pharmacokinetic study was conducted in which the prodrug was administered by intravenous 
administration. This serves as supplemental information to the work from Chapter 4. 
 
Methods 
Pharmacokinetic Study 
 The pharmacokinetics of DTPA penta-ethyl ester and its metabolites were evaluated 
following a single, intravenous injection of [14C]DTPA penta-ethyl ester in female Sprague 
Dawley rats (Charles River, Morrisville, NC). Four rats with jugular vein catheters were 
administered with DTPA penta-ethyl ester at a dose of 15 µmol kg-1 using a mixture of 
radiolabeled and non-radiolabeled DTPA penta-ethyl ester. The radioactive dose was 14.8 MBq 
kg-1. The dosing solutions were prepared in a sterile vehicle of pH 7.4 phosphate buffered saline 
and administered at a volume of 1 mL kg-1. The rats were fasted for 6 h prior to dosing and 
housed in individual metabolic cages for the duration of the study. Food was presented 4 h after 
dosing while water was made freely accessible throughout the study. 
The study was conducted over 24 h, at which time the rats were euthanized. Blood, 
urine, and feces were collected at 1, 2, 4, 8, 12, and 24 h after dosing. Blood was obtained via 
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the jugular vein catheters and immediately transferred to collection tubes containing sodium 
fluoride and potassium oxalate. Upon blood collection, the tubes were inverted several times 
before centrifuging at 3500 RPM for 5 min to isolate the plasma fraction. For assay, aliquots of 
plasma and urine were added directly to 10 mL of scintillation cocktail (Ultima Gold, Perkin 
Elmer, Waltham, MA). The LSC data were corrected for quenching using an external standard. 
The feces were diluted with a 1:1 mixture of acetonitrile and pH 4, 25 mM citrate buffer 
and homogenized in polycarbonate vials containing steel grinding balls. The homogenization 
was performed by shaking the vials on the high throughput homogenizer (PowerGen, Thermo 
Fisher Scientific, Waltham, MA) for 5-8 min at high speeds. Approximately 200 mg of each 
homogenate was sampled and combined with 1 mL of Solvable (Perkin Elmer) and heated in an 
oven at 60°C for 1-3 h until digestion was visibly complete. Once the samples were cooled, 
hydrogen peroxide (30% in water) was added in two aliquots of 100 µL to de-colorize the 
sample. The samples were returned to the 60°C oven for an additional 1 h. After cooling, each 
sample was diluted with 10 mL of scintillation cocktail. 
All samples were analyzed by liquid scintillation counting (LSC; Tri-Carb 3110 TR, 
Perkin Elmer). The radioactivity measured in the urine and feces samples at each time point 
were weight-corrected to determine the total amount that was excreted. The LSC data were 
used to construct profiles for 14C in the plasma, urine, and feces. The pharmacokinetic 
parameters were calculated by non-compartmental analysis using linear trapezoidal calculations 
(Phoenix WinNonlin, Pharsight, Cary, NC). 
 
Results 
 The plasma concentration of 14C exhibited a bi-phasic profile following the intravenous 
injection of [14C]DTPA penta-ethyl ester. The profiles for the individual rats, shown in Figure 19, 
had a mean concentration of approximately 9 nmol mL-1 at the first time point of 1 h. Within 8 h, 
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the concentration declined to approximately 70% of the initial levels. From non-compartmental 
analysis, the AUC0-inf was calculated to be 79.5 h nmol mL
-1 and the volume of distribution was 
0.64 L. The clearance and half-life were determined to be 0.043 L h-1 and 10.3 h, respectively. 
 The excretion profiles of 14C were highly variable. The cumulative excretion of 14C in 
urine and feces for the individual rats appear in Figure 20 and Figure 21, respectively. The 
cumulative excretion of 14C in urine ranged from 28% to 47% of the administered dose over the 
24 h period. Approximately 70% of these cumulative totals were excreted within 4 h of 
administration. Likewise, the cumulative fecal excretion of 14C ranged from 14% to 38%. The 
excretion in feces was minimal during the first 8 h after administration, and greater than 90% of 
the cumulative total was excreted after 8 h. In total, approximately 63% of the administered 
dose was excreted in urine and feces over 24 h. 
 
Discussion 
 A comparison of the pharmacokinetic parameters from the intravenous injections of 
DTPA and DTPA penta-ethyl ester revealed significant differences. Previously reported 
parameters for DTPA and their comparisons to DTPA penta-ethyl ester are summarized in 
Table 11 (47). The dose-normalized exposure with the prodrug was more than 20-fold higher 
than with DTPA. The clearance was significantly lower with the prodrug by nearly 6-fold. The 
volume of distribution was also higher by greater than 3-fold. Collectively, these parameters 
indicate that administration of DTPA penta-ethyl ester resulted in longer systemic circulation 
time and higher tissue distribution. As discussed in Chapter 4, these may be favorable attributes 
for radionuclide decorporation depending on the circumstances of contamination. By increasing 
circulation time, the availability of the chelating agent in the blood may be more aligned with the 
contaminants under certain conditions. In addition, the higher tissue distribution may translate 
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into an improvement in the ability of the chelating agent to facilitate decorporation from the 
intracellular compartments of tissues. 
 The excretion profiles after the intravenous administration provide additional insight into 
the disposition of DTPA penta-ethyl ester. The urinary excretion of 14C after intravenous 
administration is consistent with the high urinary excretion observed following oral 
administration. This confirms that renal clearance is the major mechanism of elimination. 
However, unlike DTPA, which is excreted predominantly in urine, elevated levels of 14C were 
found in feces, indicating that DTPA penta-ethyl ester or its intermediates can undergo biliary 
clearance. The amount of 14C excreted in feces represents approximately 24% of the 
administered dose, or nearly 40% of the total 14C excreted in urine and feces over 24 hours. 
This suggests that biliary clearance plays a large role in the total elimination. This also helps to 
explain the high levels of 14C that were found in the gastrointestinal tract from the biodistribution 
study.  
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Tables 
Table 11 Pharmacokinetic parameters for DTPA and DTPA penta-ethyl ester 
Comparison of pharmacokinetic parameters derived from non-compartmental analysis following 
the administration of DTPA and DTPA penta-ethyl ester in rats 
Treatment 
Route 
Dose (µmol kg-1) 
DTPA f 
IV 
29.4 
DTPA prodrug 
IV 
15 
DTPA prodrug 
PO 
187 
AUC0-inf (h nmol mL-1)a 7.1 79.5 974 
Vd (L)b 0.18 0.64 N/A 
CL (L h-1)c 0.25 0.043 N/A 
t1/2 (h)d 0.53 10.3 N/A 
MRT (h)e 0.73 12.9 N/A 
a. AUC0-inf: area under the curve 
b. Vd: volume of distribution 
c. CL: clearance 
d. t1/2: half-life 
e. MRT: mean residence time 
f. Data adapted from (47) 
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Figures 
 
Figure 19 Plasma concentration of 14C from the IV administration of [14C]DTPA prodrug 
Plasma concentration profile of 14C in rats after the IV administration of 15 µmol kg-1 DTPA 
penta-ethyl ester; data expressed as profiles for individual rats 
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Figure 20 Urinary excretion of 14C from the IV administration of [14C]DTPA prodrug 
Urinary excretion profile of 14C in rats after the IV administration of 15 µmol kg-1 DTPA penta-
ethyl ester; data expressed as profiles for individual rats 
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Figure 21 Fecal excretion of 14C from the IV administration of [14C]DTPA prodrug 
Fecal excretion profile of 14C in rats after the IV administration of 15 µmol kg-1 DTPA penta-ethyl 
ester; data expressed as profiles for individual rats 
0
10
20
30
40
50
0 4 8 12 16 20 24 28
E
xc
re
te
d
 14
C
 -
cu
m
u
la
ti
ve
 (%
 o
f 
ad
m
in
is
te
re
d
)
Time (h)
92 
 
 
 
REFERENCES 
 
 (1)  Coleman CN, Hrdina C, Bader JL, Norwood A, Hayhurst R, Forsha J, et al. Medical 
response to a radiologic/nuclear event: integrated plan from the Office of the Assistant 
Secretary for Preparedness and Response, Department of Health and Human Services. 
Ann Emerg Med 2009;53(2):213-22. 
 (2)  Cassatt DR, Kaminski JM, Hatchett RJ, DiCarlo AL, Benjamin JM, Maidment BW. 
Medical countermeasures against nuclear threats: radionuclide decorporation agents. 
Radiat Res 2008;170:540-8. 
 (3)  Fisher DR. Decorporation: officially a word. Health Phys 2000;78(5):563-5. 
 (4)  Taylor DM, Stradling GN, Henge-Napoli MH. The scientific background to decorporation. 
Radiat Prot Dosimetry 2000;87(1):11-8. 
 (5)  Anderegg G, Arnaud-Neu F, Delgado R, Felcman J, Popov K. Critical evaluation of 
stability constants of metal complexes of complexones for biomedical and environmental 
applications. Pure Appl Chem 2005;77(8):1445-95. 
 (6)  Ansoborlo E, Prat O, Moisy P, Den Auwer C, Guilbaud P, Carriere M, et al. Actinide 
speciation in relation to biological processes. Biochimie 2006;88(11):1605-18. 
 (7)  Ansoborlo E, Amekraz B, Moulin C, Moulin V, Taran F, Bailly T, et al. Review of actinide 
decorporation with chelating agents. C R Chim 2007;10(10):1010-9. 
 (8)  Baybarz RD. Dissociation constants of the transplutonium element chelates of 
diethylenetriaminepentaacetic acid (DTPA) and the application of DTPA chelates to 
solvent extraction separations of transplutonium elements from the lanthanide elements. 
Polyhedron 1965;27(8):1831-9. 
 (9)  Caravan P, Ellison JJ, McMurry TJ, Lauffer RB. Gadolinium (III) chelates as MRI 
contrast agents: structure, dynamics, and applications. Chem Rev 1999;99(9):2293-352. 
 (10)  Benes DM, Burnett CL. Final report on the safety assessment of pentasodium pentetate 
and pentetic acid as used in cosmetics. Int J Toxicol 2007;27:71-92. 
 (11)  Sillanpaa M, Sihvonen ML. Analysis of EDTA and DTPA. Talanta 1997;44(8):1487-97. 
 (12)  Hameln Pharmaceuticals. Package insert. Pentetate calcium trisodium, NDA 021749.  
2004 Aug 11.  
93 
 
 (13)  Hameln Pharmaceuticals. Package insert. Pentetate zinc trisodium, NDA 021751.  2004 
Aug 11.  
 (14)  Crawley FEH, Haines JW. The dosimetry of carbon-14 labelled compounds: the 
metabolism of diethylenetriamine pentaacetic acid (DTPA) in the rat. Int J Nucl Med Biol 
1979;6(1):9-15. 
 (15)  Stevens E, Rosoff B, Weiner M, Spencer H. Metabolism of the chelating agent 
diethylenetriamine pentaacetic acid (C14DTPA) in Man. Exp Biol and Med 
1962;111(2):235-8. 
 (16)  Stradling GN, Henge-Napoli MH, Paquet F, Poncy JL, Fritsch P, Taylor DM. Optimum 
treatment regimens with animals. Radiat Prot Dosimetry 2000;87(1):29-40. 
 (17)  Menetrier F, Grappin L, Raynaud P, Courtay C, Wood R, Joussineau S, et al. Treatment 
of accidental intakes of plutonium and americium: guidance notes. Appl Radiat Isot 
2005;62(6):829-46. 
 (18)  Keith S, Ingerman L, McCartney RA, Chappell LL, Wohlers DW, Sage GW, et al. 
Toxicological profile for americium.  Agency for Toxic Substances and Disease Registry, 
US Department of Health and Human Services; 2004.  
 (19)  Runde WH, Schulz WW. Americium. In: Morss LR, Edelstein NM, Fuger J, editors. The 
Chemistry of the Actinide and Transactinide Elements. Netherlands: Springer; 2006. p. 
1265-395. 
 (20)  Durbin PW. Actinides in animals and man. In: Morss LR, Edelstein NM, Fuger J, editors.  
The chemistry of the actinide and transactinide elements. Netherlands: Springer; 2006. 
p. 3339-440. 
 (21)  Cooper JR, Gowing HS. The binding of americium and curium to human serum proteins. 
Int J Radiat Biol 1981;40(5):569-72. 
 (22)  Taylor DM. The bioinorganic chemistry of actinides in blood. J Alloys Compd 
1998;271:6-10. 
 (23)  Turner GA, Taylor DM. The transport of plutonium, americium and curium in the blood of 
rats. Phys Med Biol 1968;13(4):535-546. 
 (24)  Fritsch P, Serandour AL, Gremy O, Phan G, Tsapis N, Fattal E, et al. Structure of a 
single model to describe plutonium and americium decorporation by DTPA treatments. 
Health Phys 2010;99(4):553-9. 
 (25)  Taylor DM, Hodgson SA, Stradling N. Treatment of human contamination with plutonium 
and americium: would orally administered Ca- or Zn-DTPA be effective? Radiat Prot 
Dosimetry 2007;127(1-4):469-71. 
 (26)  Lloyd RD, Taylor GN, Mays CW, Jones CW, Bruenger FW, Atherton DR. Dependency of 
chelation efficacy upon time after first DTPA injection. Radiat Res 1979;78(3):448-54. 
94 
 
 (27)  Stradling GN, Henge-Napoli MH, Paquet F, Poncy JL, Fritsch P, Taylor DM. Approaches 
for experimental evaluation of chelating agents. Radiat Prot Dosimetry 2000;87(1):19-28. 
 (28)  Robinson B, Heid KR, Aldridge TL, Glenn RD. 1976 Hanford americium exposure 
incident: organ burden and radiation dose estimates. Health Phys 1983;45(4):911-21. 
 (29)  Breitenstein Jr BD, Palmer HE. Lifetime follow-up of the 1976 americium accident victim. 
Radiat Prot Dosimetry 1989;26(1-4):317-22. 
 (30)  Breustedt B, Blanchardon E, Berard P, Fritsch P, Giussani A, Lopez MA, et al. Biokinetic 
modelling of DTPA decorporation therapy: the CONRAD approach. Radiat Prot 
Dosimetry 2009;134(1):38-48. 
 (31)  Guilmette RA, Durbin PW. Scientific basis for the development of biokinetic models for 
radionuclides-contaminated wounds. Radiat Prot Dosimetry 2003;105(1-4):213-7. 
 (32)  Volf V. Effect of drinking Zn-DTPA on 238-Pu and 241-Am in rat bones. Radiat Environ 
Biophys 1984;23(2):141-3. 
 (33)  Stella V. A Case for Prodrugs. In: Stella V, Borchardt R, Hageman M, Oliyai R, Maag H, 
Tilley J, editors. Prodrugs. New York: Springer; 2007. p. 3-33. 
 (34)  Rautio J, Kumpulainen H, Heimbach T, Oliyai R, Oh D, Jarvinen T, et al. Prodrugs: 
design and clinical applications. Nat Rev Drug Discov 2008;7(3):255-70. 
 (35)  Reddy JD, Cobb RR, Dungan NW, Matthews LL, Aiello KV, Ritter G, et al. Preclinical 
toxicology, pharmacology, and efficacy of a novel orally administered 
diethylenetriaminepentaacetic acid (DTPA) formulation. Drug Dev Res 2012;73(5):232-
42. 
 (36)  Shankar GN, Weber W, Doyle-Eisele M, Guilmette RA. Efficacy of a novel orally 
administered formulation of DTPA tablets for decorporating an intravenously injected 
radionuclide: a comparison with intravenously administered licensed DTPA. Drug Dev 
Res 2012;73(5):290-8. 
 (37)  Ettmayer P, Amidon GL, Clement B, Testa B. Lessons learned from marketed and 
investigational prodrugs. J Med Chem 2004;47(10):2393-404. 
 (38)  Beaumont K, Webster R, Gardner I, Dack K. Design of ester prodrugs to enhance oral 
absorption of poorly permeable compounds: challenges to the discovery scientist. Curr 
Drug Metab 2003;4(6):461-85. 
 (39)  Liederer BM, Borchardt RT. Enzymes involved in the bioconversion of esterbased 
prodrugs. J Pharm Sci 2006;95(6):1177-95. 
 (40)  Imai T. Human carboxylesterase isozymes: catalytic properties and rational drug design. 
Drug Metab Pharmacokinet 2006;21(3):173-85. 
 (41)  Satoh T, Hosokawa M. The mammalian carboxylesterases: from molecules to functions. 
Annu Rev Pharmacol Toxicol 1998;38(1):257-88. 
95 
 
 (42)  ChemBioDraw Ultra 11.0.1. Cambridge, MA: Cambridgesoft; 2012.  
 (43)  Di L, Kerns EH. Profiling drug-like properties in discovery research. Curr Opin Chem Biol 
2003;7(3):402-8. 
 (44)  Guilmette RA, Parks JE, Lindenbaum A. Synthesis and therapeutic testing of mono- and 
dialkyl esters of pentetic (diethylenetriaminepentaacetic) acid for decorporation of 
polymeric plutonium. J Pharm Sci 1979;68(2):194-6. 
 (45)  Markley JF. Removal of polymeric plutonium from mice by combined therapy with the 
calcium chelate and penta-ethyl ester of DTPA. Int J Radiat Biol 1963;7(4):405-7. 
 (46)  Bullard W. Consequence management: medical countermeasures. Drug Dev Res 
2012;73(5):274-80. 
 (47)  Phan G, Herbet A, Cholet S, Benech H, Deverre JR, Fattal E. Pharmacokinetics of 
DTPA entrapped in conventional and long-circulating liposomes of different size for 
plutonium decorporation. J Control Release 2005;110(1):177-88. 
 (48)  Sadgrove MP, Leed MG, Shapariya S, Madhura DB, Jay M. Evaluation of a DTPA 
prodrug, C2E5 as an orally bioavailable radionuclide decorporation agent. Drug Dev Res 
2012;73(5):243-51. 
 (49)  Wood R, Sharp C, Gourmelon P, Le Guen B, Stradling GN, Taylor DM, et al. 
Decorporation treatment- medical overview. Radiat Prot Dosimetry 2000;87(1):51-6. 
 (50)  Hoehler FK. Logistic equations in the analysis of S-shaped curves. Comput Biol Med 
1995;25(3):367-71. 
 (51)  Catsch A, Le DK, Chambault D. Evaluation of the efficacy of different metal chelates of 
DTPA in removing internally-deposited radionuclides. Int J Radiat Biol 1964;8(1):35-43. 
 (52)  Seidel A. Comparison of the effectiveness of CaDTPA and ZnDTPA in removing 241 Am 
from the rat. Radiat Res 1973;54(2):304-15. 
 (53)  Durbin PW, Schmidt CT. Predicting the kinetics of chelating agents in man from animal 
data. Health Phys 1989;57:165-74. 
 (54)  Guilmette RA, Muggenburg BA. Reducing the radiation dose from inhaled americium-
241 using continuously administered DTPA therapy. Int J Radiat Biol 1988;53(2):261-71. 
 (55)  Stradling GN, Stather JW, Gray SA, Moody JC, Ellender M, Hodgson A, et al. The 
efficacies of pure LICAM(C) and DTPA on the retention of plutonium-238 and 
americium-241 in rats after their inhalation as nitrate and intravenous injection as citrate. 
Int J Radiat Biol 1989;56(4):503-14. 
 (56)  Keith S, Demchuk E, Williams RL, Aufderheide E, Coles C, Wohlers DW, et al. 
Toxicological profile for plutonium.  Agency for Toxic Substances and Disease Registry, 
US Department of Health and Human Services; 2010.  
96 
 
 (57)  Gerber GB, Thomas RG. Methods of treatment. Radiat Prot Dosimetry 1992 May 
1;41(1):27-36. 
 (58)  Stather JW, Smith H, Bailey MR, Birchall A, Bulman RA, Crawley FEH. The retention of 
14C-DTPA in human volunteers after inhalation or intravenous injection. Health Phys 
1983;44(1):45-52. 
 (59)  Lloyd RD, Jones CW, Taylor GN, Mays CW, Atherton DR. Pu and Am decorporation in 
beagles: effects of magnitude of initial Ca-DTPA injection upon chelation efficacy. Radiat 
Res 1979;79(3):630-4. 
 (60)  Taylor DM, Sowby FD. The removal of americium and plutonium from the rat by 
chelating agents. Phys Med Biol 1962;7(1):83-91. 
 (61)  Bruenger FW, Kuswik-Rabiega G, Miller SC. Decorporation of aged americium deposits 
by oral administration of lipophilic polyamino carboxylic acids. J Med Chem 
1992;35(1):112-8. 
 (62)  Miller SC, Wang X, Bowman BM. Pharmacological properties of orally available, 
amphipathic polyaminocarboxylic acid chelators for actinide decorporation. Health Phys 
2010;99(3):408-12. 
 (63)  Lachenmeier DW, Haupt S, Schulz K. Defining maximum levels of higher alcohols in 
alcoholic beverages and surrogate alcohol products. Regul Toxicol and Pharmacol 
2008;50(3):313-21. 
 (64)  Jay M, Mumper RJ, inventors; Methods and pharmaceutical compositions for 
decorporation of radioactive compounds.U.S. Patent No. 8,030,358. 2011 Oct 4. 
 (65)  United States Pharmacopeia 34 - National Formulary 29. Rockville, MD: United States 
Pharmacopeia Convention; 2011. 
 (66)  Sudmeier JL, Reilley CN. Nuclear magnetic resonance studies of protonation of 
polyamine and aminocarboxylate compounds in aqueous solution. Anal Chem 
1964;36(9):1698-706. 
 (67)  Sherry AD, Cacheris WP, Kuan K. Stability constants for Gd3+ binding to model DTPA-
conjugates and DTPA-proteins: implications for their use as magnetic resonance 
contrast agents. Magn Reson Med 1988;8(2):180-90. 
 (68)  Lee CP, de Vrueh RL, Smith PL. Selection of development candidates based on in vitro 
permeability measurements. Adv Drug Deliv Rev 1997;23(1):47-62. 
 (69)  Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational 
approaches to estimate solubility and permeability in drug discovery and development 
settings. Adv Drug Deliv Rev 1997;23(1):3-25. 
 (70)  Fleisher D, Li C, Zhou Y, Pao LH, Karim A. Drug, meal and formulation interactions 
influencing drug absorption after oral administration. Clin Pharmacokinet 
1999;36(3):233-54. 
97 
 
 (71)  Lokshina LA, Orekhovich VN, Sklyankina VA. Esterase activity of pepsin. Nature 
1964;204:580. 
 (72)  MacGregor KJ, Embleton JK, Lacy JE, Perry EA, Solomon LJ, Seager H, et al. Influence 
of lipolysis on drug absorption from the gastro-intestinal tract. Adv Drug Deliv Rev 
1997;25(1):33-46. 
 (73)  Gao P, Morozowich W. Development of supersaturatable self-emulsifying drug delivery 
system formulations for improving the oral absorption of poorly soluble drugs. Expert 
Opin Drug Deliv 2005;3(1):97-110. 
 (74)  Porter CJ, Trevaskis NL, Charman WN. Lipids and lipid-based formulations: optimizing 
the oral delivery of lipophilic drugs. Nat Rev Drug Discov 2007;6(3):231-48. 
 (75)  Hosokawa M. Structure and catalytic properties of carboxylesterase isozymes involved 
in metabolic activation of prodrugs. Molecules 2008;13(2):412-31. 
 (76)  Bruenger FW, Stevens W, Stover BJ. Americium-241 in the blood: in vivo and in vitro 
observations. Radiat Res 1969;37(2):349-60. 
 (77)  Stradling GN, Taylor DM, Henge-Napoli MH, Wood R, Silk TJ. Treatment for actinide-
bearing industrial dusts and aerosols. Radiat Prot Dosimetry 2000;87(1):41-50. 
 (78)  Sueda K, Sadgrove MP, Fitzsimmons JM, Jay M. Physicochemical characterization of a 
prodrug of a radionuclide decorporation agent for oral delivery. J Pharm Sci 
2012;101(8):2844-53. 
  (79) National Research Council 1996. Guide for the care and used of laboratory animals, 
Washington, DC: National Academy Press. 
 (80)  Crawley FEH, Haines JW. The dosimetry of carbon-14 labelled compounds: The 
metabolism of diethylenetriamine pentaacetic acid (DTPA) in the rat. Int J Nucl Med Biol 
1979;6(1):9-15. 
 (81)  Derelanko MJ 2000. Toxicologist's pocket handbook, Boca Raton: CRC Press. 
 (82)  Stather JW, Stradling GN, Gray SA, Moody J, Hodgson A. Use of DTPA for increasing 
the rate of elimination of plutonium-238 and americium-241 from rodents after their 
inhalation as the nitrates. Hum Toxicol 1985;4(6):573-82. 
 (83)  Reddy JD, Cobb RR, Dungan NW, Matthews LL, Aiello KV, Ritter G, et al. Preclinical 
toxicology, pharmacology, and efficacy of a novel orally administered 
diethylenetriaminepentaacetic acid (DTPA) formulation. Drug Dev Res 2012;73(5):232-
42. 
 (84)  Shankar GN, Weber W, Doyle-Eisele M, Guilmette RA. Efficacy of a novel orally 
administered formulation of DTPA tablets for decorporating an intravenously injected 
radionuclide: a comparison with intravenously administered licensed DTPA. Drug Dev 
Res 2012;73(5):290-8. 
98 
 
 (85)  Zhang Y, Sadgrove MP, Mumper RJ, Jay M. Radionuclide decorporation: matching the 
biokinetics of actinides by transdermal delivery of pro-chelators. AAPS J 
2013;15(4):1180-8. 
 (86)  Zhang Y, Sadgrove MP, Mumper RJ, Jay M. Transdermal prodrug delivery for 
radionuclide decorporation: nonaqueous gel formulation development and in vitro and in 
vivo assessment. Drug Dev Res 2013;74:322-31. 
 (87)  van Breemen RB, Li Y. Caco-2 cell permeability assays to measure drug absorption. 
Expert Opin Drug Metab Toxicol 2005;1(2):175-85. 
 (88)  Press B, Di Grandi D. Permeability for intestinal absorption: Caco-2 assay and related 
issues. Curr Drug Metab 2008;9(9):893-900. 
 (89)  Cheng KC, Li C, Uss AS. Prediction of oral drug absorption in humans- from cultured cell 
lines and experimental animals. Expert Opin Drug Metab Toxicol 2008;4(5):581-90. 
 (90)  Gan LS, Yanni S, Thakker D. Modulation of the tight junctions of the Caco-2 Cell 
monolayers by H2-antagonists. Pharm Res 1998;15(1):53-7. 
 (91)  Imai T, Imoto M, Sakamoto H, Hashimoto M. Identification of esterases expressed in 
Caco-2 cells and effects of their hydrolyzing activity in predicting human intestinal 
absorption. Drug Metab Dispos 2005;33(8):1185-90. 
 (92)  Ohura K, Sakamoto H, Ninomiya Si, Imai T. Development of a novel system for 
estimating human intestinal absorption using Caco-2 cells in the absence of esterase 
activity. Drug Metab Dispos 2010;38(2):323-31. 
 
